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 ABSTRACT 
 Lung cancer is the leading cause of cancer related death, accounting for one 
third of all deaths from cancer worldwide. About 85-90% of lung cancers are non-
small cell lung cancer (NSCLC). Treatment approach for NSCLC varies depending 
on the stage of cancer, overall health of the patient, lung function and symptoms. 
The common treatment options involve surgery, radiation therapy or chemotherapy 
involving combination of platinum based compounds. Chemo and radio-therapy 
offers short-term improvement in disease related symptoms in patients with 
advanced NSCLC; however the impact of chemo and radio-therapy on quality of 
patient's life remains a major concern.  
 Molecular targeted therapies provide a treatment option in addition to 
conventional cancer treatments. The efficacy of the targeted therapies remains 
restricted to the cancer cells with oncogene addiction. Oncogene addiction refers to 
the phenomenon in which cancer cells that contain multiple genetic and epigenetic 
changes remain addicted to one or a few genes for both maintenance of the 
malignant phenotype and cell survival. One such oncogene that has been 
extensively targeted for treatment of NSCLC is mutant epidermal growth factor 
receptor (EGFR), which is effectively blocked by EGFR tyrosine kinase inhibitors 
(TKIs). However, the development of resistance to EGFR TKIs continues to be the 
major limitation in the treatment of NSCLC. Resistance to EGFR TKIs in several 
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cancers including NSCLC has been associated with the loss of canonical epithelial 
protein E-cadherin, suggesting involvement of EMT in conferring EGFR TKI 
resistance. Transcription factors are known to play a central role in inducing EMT. 
 TGF-β, a secreted protein and a potent inducer of EMT is known to directly 
activate transcription factor SNAIL to exert its effect. Our lab previously found that 
transcription factor SNAIL was significantly upregulated in in vitro model of EMT 
generated by chronic exposure of EGFR mutant NSCLC cell line to TGF-β. Further, 
TGF-β exposed EGFR mutant NSCLC having high SNAIL expression were resistant 
to EGFR TKIs. Moreover, withdrawal of TGF-β exposure resulted in reversal of 
mesenchymal phenotype and restored sensitivity of EGFR mutant NSCLC to EGFR 
TKIs. Consequently, we hypothesized that SNAIL induced mesenchymal transition 
promotes EGFR TKI resistance in EGFR mutant NSCLC. We further hypothesized 
that acquired EGFR TKI resistance can be reversed by promoting epithelial 
phenotype. To test our hypothesis, we developed an in vitro model of EMT by 
ectopically overexpressing SNAIL in EGFR mutant NSCLC cells. Our studies 
showed that ectopic SNAIL overexpression rendered EGFR mutant NSCLC 
resistant to EGFR TKI.  
 Further to investigate if EGFR TKI sensitivity of EGFR mutant NSCLC is 
restored on reversing mesenchymal phenotype, we developed doxycycline inducible 
SNAIL expressing EGFR mutant NSCLC cell lines. We were able to control 
epithelial and mesenchymal phenotype by doxycycline inducible SNAIL expression. 
Thus far, we developed an in vitro model of EMT which can be used to investigate 
 
 
xiv 
 
molecular mechanisms affecting EGFR TKI sensitivity in EGFR mutant NSCLC. 
Further studies to investigate whether or not reversing mesenchymal phenotype 
restores EGFR TKI sensitivity of EGFR mutant NSCLC need to be done. 
 In summary, our data suggests that development of drugs targeting 
transcription factor SNAIL is a promising strategy in overcoming EGFR TKI 
resistance and enhancing the efficacy of molecular targeted therapy in EGFR 
mutant NSCLC. 
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CHAPTER ONE 
INTRODUCTION 
Pathophysiology of Lung Cancer 
 Lung cancer is the leading cause of cancer related death, accounting for one 
third of all deaths from cancer worldwide (1). The most common symptoms of lung 
cancer include persistent cough or chest pain. Other symptoms include hemoptysis, 
malaise, weight loss, dyspnea and hoarseness of voice (2). Presence of lung cancer 
can be determined from patient's history, physical examination, routine laboratory 
evaluations, chest x-ray, chest computed tomography (CT) scan with infusion of 
contrast material or biopsy (2). The vast majority of lung cancers are carcinomas -
malignancies arising from epithelial cells (3). Lung cancers are categorized by the 
size and appearance of the malignant cells under the microscope. The two broad 
classes are non-small cell lung carcinoma (NSCLC) and small-cell lung carcinoma 
(SCLC) (3). These 2 types of lung cancer are often treated very differently. 
  About 85-90% of lung cancers are NSCLC (4). NSCLC is a heterogeneous 
aggregate of histologies. The most common histologies include squamous cell 
carcinoma, adenocarcinoma and large cell carcinoma (2). NSCLC arises from the 
epithelial cells of the lung from the central bronchi to terminal alveoli. The 
histological type of NSCLC correlates with site of origin reflecting the variation in 
respiratory tract epithelium of the bronchi to alveoli. Squamous cell carcinoma 
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usually starts near a central bronchus. Adenocarcinoma and large cell carcinoma 
usually originate in peripheral lung tissue. These histologies are classified together 
because approaches to their diagnosis, staging, prognosis and treatment are similar 
(2). Although NSCLCs are associated with cigarette smoking, adenocarcinomas 
may be found in patients who have never smoked (2, 4). 
 
Treatment of NSCLC 
 Treatment approach for NSCLC varies depending on the stage of cancer, 
overall health of the patient, lung function and symptoms. The common treatment 
options involve surgery, radiation therapy or chemotherapy involving combination of 
platinum based compounds (4). Surgery is the most potential curative option for this 
disease if the tumor is diagnosed in an early stage. Surgical options involve 
pneumonectomy-surgical removal of entire lung, lobectomy-surgical removal of an 
entire section (lobe) of a lung and segmentectomy or wedge resection-surgical 
removal of a part of a lobe (4). Chemotherapy offers short-term improvement in 
disease related symptoms in patients with advanced NSCLC. Most often a 
combination of 2 chemotherapeutic agents is used as a treatment regimen for 
NSCLC. Some of the chemotherapeutic agents used for treatment of NSCLC are 
cisplatin, carboplatin, paclitaxel, gemcitabine, vinblastine and etoposide (4). 
However the impact of chemotherapy on the quality of patient's life remains a major 
concern (5). For people with advanced NSCLC who meet certain criteria, targeted 
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therapies may be added to the treatment as an adjuvant to chemotherapy or as a 
first line treatment. 
 
Targeted therapies for NSCLC 
 Targeted therapies are medications that are designed to treat cancer by 
interfering with the specific molecular abnormalities or biochemical pathways that 
drive the abnormal growth and spread of cancer (2). Targeted therapies are 
designed to predominantly attack abnormal signaling molecules so that they would 
be more effective and have less side effects as compared to traditional 
chemotherapeutic agents.  Over the past decade, a multitude of targeted agents 
have been explored for the treatment of advanced NSCLC and clinical trials so far 
have yield encouraging results.  
 
Angiogenesis inhibitors 
 Angiogenesis or development of new blood vessels to supplement nutrition 
and oxygenation to the tissue is an essential process for the growth of tumors. 
Vascular epidermal growth factor (VEGF) is an important growth factor that control 
angiogenesis in normal and tumor cells (6). VEGF is frequently overexpressed in 
NSCLC and associated with tumor progression. Bevacizumab (Avastin), a 
humanized mouse monoclonal antibody that binds to VEGF has been shown to 
provide significant survival benefits when used in combination with platinum based 
chemotherapy as a first line treatment for a subset of advanced NSCLC (3, 7). 
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However in phase II study of this combination treatment, high rate of fatal pulmonary 
hemorrhages was found to be associated with bevacizumab treatment which limits 
the use of this drug (7).   
Epidermal growth factor receptor inhibitors 
 Epidermal growth factor receptor (EGFR) is a cell surface receptor, a 
member of ErbB family of receptor tyrosine kinases (8). Binding of EGFR to its 
cognate ligands leads to autophosphorylation of receptor tyrosine kinase and 
subsequent activation of EGFR signaling pathways. Activation of EGFR signaling 
pathways has many effects including cell proliferation, differentiation and survival. 
These effects are mediated by a series of signaling mechanisms such as activation 
of mitogen activated protein kinase (MAPK) and phosphatidylinositol 3-kinase (PI3K) 
pathways (9, 10). Although present in normal cells, EGFR is frequently 
overexpressed in a variety of tumor cells and is associated with poor prognosis and 
decreased survival (8, 11). More than 60% of NSCLC have altered expression of 
EGFR, as a result EGFR is considered to be an important therapeutic target for 
treatment of NSCLC (11, 12). Currently available EGFR targeted therapies for 
NSCLC include small molecule EGFR tyrosine kinase inhibitors (TKIs) - erlotinib 
(Tarceva), gefitinib (Iressa) and monoclonal antibodies targeting the extracellular 
domain of EGFR - cetuximab (Erbitux) and panitumimab (Vectibix) (3, 11, 13). 
Although erlotinib has shown to prolong patient survival in large phase III trials, 
patients who initially respond to EGFR TKIs eventually develop resistance (14). 
Further, there was no clinical benefit when gefitinib was combined with 
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chemotherapy in two similar trials INTACT-1 and INTACT-2 (15, 16). Although the 
pharmacological profile of erlotinib and gefitinib is similar, one reason attributed to 
the failure of gefitinib in INTACT-1 and INTACT-2 trials is ethnic variability (17). 
Gefitinib is found to be more effective in female patients of Asian origin and non-
smokers indicating that an appropriate patient selection based on genetic and 
clinical characteristic should be employed for both future clinical trials and clinical 
use of gefitinib (17). Clinical use of monoclonal antibodies cetuximab and 
panitumimab for advanced NSCLC is very limited owing to the large variations in 
responses observed during clincial trials evaluating efficacy of these drugs.  
Although cetuximab in combination with chemotherapy showed significant efficacy in 
Phase II trials (18, 19), subsequent phase III trials BMS-099 (cetuximab plus 
taxane/carboplatin) and FLEX (cetuximab plus cisplatin/vinorelbine) failed to 
observe a significant  improvement in overall survival of patients with advanced 
NSCLC (20, 21). The controversial results of trials involving cetuximab necessitates 
the ongoing search to identify a selection marker which might identify a population of 
NSCLC patients that benefit with cetuximab treatment.  
  
Anaplastic large cell lymphoma kinase inhibitors  
Anaplastic large cell lymphoma kinase (ALK) gene encodes a receptor 
tyrosine kinase that is normally expressed only in certain neuronal cells. ALK gene 
can be oncogenic either due to formation of a fusion gene as a result of genetic 
rearrangements, gene amplification or mutations in ALK gene itself. ALK 
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rearrangements are identified in about 7% of NSCLC patients (22). Majority of 
rearrangements in NSCLC result due to complex deletion and inversion in 
chromosome 2p resulting in Echinoderm microtubule associated protein-like 4 
(EML4)-ALK fusion gene product. EML4-ALK fusion protein results in constitutive 
ALK kinase activity contributing to carcinogenesis (22). FDA approved crizotinib 
(Xalkori) to treat certain advanced NSCLC expressing EML4-ALK fusion gene (23) . 
Early clinical studies showed dramatic response of crizotinib among EML4-ALK 
positive patients and phase III trials testing the efficacy of crizotinib versus standard 
chemotherapy in advanced ALK positive lung cancer demonstrated higher rate of 
progression free survival with crizotinib treatment as compared to chemotherapy 
(24). However, multiple novel mutations in ALK that confer resistance to crizotinib 
have been identified, limiting the clinical use of crizotinib (25, 26).  
 
RAS/RAF/MEK/ERK pathway inhibitors 
 RAS/RAF/MEK/ERK pathway is an important route that regulates cell 
proliferation and survival. A number of cell surface receptors including EGFR can 
activate RAS/RAF/MEK/ERK pathway (27). The RAS/RAF/MEK/ERK pathway is a 
kinase cascade where a number of kinases from RAF to MEK to ERK are 
sequentially activated in response to an extracellular growth signal. RAS family of 
proto-oncogene that consists of KRAS, HRAS and NRAS are plasma membrane 
bound G proteins that regulate a number of signaling pathways involved in cell 
survival, proliferation and differentiation (28). In about 10-15% of NSCLC RAS 
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signaling pathway is aberrantly activated due to KRAS mutations and contributes to 
poor prognosis and tumor metastasis (29). A number of agents targeting RAS 
oncogenes are being studied of which farnesyl transferase inhibitors (FTIs) such as 
tipifarnib (Zarnestra) and lonafarnib are under clinical investigations for KRAS 
mutations harboring NSCLC (30). The RAS/RAF/MEK/ERK signaling pathway can 
also be activated by perturbations of upstream components of RAS. Aberrant 
expression or mutational activation of EGFR as observed in NSCLC can lead to 
hyperactivation of RAS causing upregulated RAS/RAF/MEK/ERK signaling (31, 32). 
In an effort to inhibit hyperactivated RAS/RAF/MEK/ERK signaling pathway, dual 
specificity kinase-MEK, a mitogen activated protein kinase kinase, which acts further 
downstream along the RAS/RAF/MEK/ERK pathway is being explored as a drug 
target for treatment of NSCLC with advanced malignancy (33). Preclinical studies of 
MEK inhibitors such as CI-1040, PD-0325901 and AZD6244 show promising 
antitumor activity (33, 34). However, phase II trials of these compounds failed to 
meet the primary efficacy end point and due to lack of responses coupled with 
safety issues, the trials were closed (35, 36).  
  
PI3K/AKT pathway inhibitors 
PI3K/AKT signal transduction pathway regulates cell survival and proliferation 
and is implicated in the development and progress of various tumors (37). Of note, 
mutations in PIK3CA, the catalytic subunit of PI3K occurs in approximately 5% of 
NSCLC resulting into constitutive activation of PI3K/AKT signaling pathway (38). 
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Drugs that inhibit PI3K are being developed for treatment of NSCLC harboring 
PIK3CA mutations. Phase I studies testing the safety profile of one such compound 
BEZ235- a competitive dual PI3K/mammalian target of rapamycin (mTOR) inhibitor 
in combination with everolimus -mTOR inhibtior for advanced solid tumors including 
NSCLC are ongoing and early trial results showed that the combination is well 
tolerated by patients (39).  
 
Heat shock protein 90 inhibitors 
 Heat shock protein 90 (Hsp90) is a member of the heat shock 
protein/chaperone family, which assists in the folding of newly synthesized proteins 
in the cell as well as in protein refolding after environmental insults (40). EGFR and 
several other kinases that contribute to deregulated signaling and proliferation in 
human cancers rely on the Hsp90 chaperone for their conformational maturation 
(41). A subset of NSCLC has been reported to be extremely sensitive to treatment 
with Hsp90 inhibitors in vitro as well as in vivo (42, 43). Potent disruption of EGFR 
maturation with Hsp90 inhibitors makes these drugs attractive targets for in depth 
clinical investigation for use in treatment of NSCLC. A phase II/III trial GALAXY-1 
testing the efficacy of Hsp90 inhibitor ganetespib in combination with 
chemotherapeutic agent docetaxel has shown beneficial effects of ganetespib on 
overall survival and progression free survival of patients with advanced metastatic 
lung cancer (44). These encouraging results are further being confirmed in a phase 
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III trial GALAXY-2 to successfully bring ganetespib to patients with advanced lung 
cancer (45). 
 
EGFR TKIs and EGFR mutations 
 The original rationale for development of EGFR targeted therapies was that 
EGFR is more abundantly expressed in lung carcinoma tissue than in adjacent 
normal lung (46). However systematic clinical trials revealed variability in clinical 
response of patients with advanced NSCLC to EGFR TKIs (47). This variability was 
explained by the discovery of somatic mutations present in the kinase domain of 
EGFR gene of a subset of NSCLC patients (31, 32). EGFR kinase domain 
mutations are present in about 10% of cases in North America and Western Europe, 
30–50% of cases in individuals of East Asian descent and are frequently associated 
with adenocarcinomas with bronchioalveolar features that arise in non-smokers and 
women (48-50).  
 Entire EGFR kinase domain is encoded by exons 18-24 of which EGFR 
kinase domain mutations target four exons 18-21 (figure1) (48, 51, 52). EGFR 
kinase domain mutations are either small in-frame deletions or amino acid 
substitutions clustered around the ATP-binding pocket of the enzyme (31, 48, 51, 
52). The most prevalent mutations are in-frame exon 19 deletions (residues 747-
750) accounting for about 45% and L858R substitution in exon 21 accounting for 40-
45% of EGFR mutations in NSCLC (Figure1)(53). Nucleotide substitutions in exon 
18 and in-frame insertions in exon 20 account for another 5% of EGFR mutations in 
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NSCLC (53). These mutations often referred to as activating mutations, increase the 
kinase activity of EGFR leading to hyperactivation of downstream cell proliferation 
and anti-apoptotic pathways and consequently confer oncogenic effects (53-55). As 
a result, NSCLCs become dependent on the mutant EGFR for cell survival and 
proliferation, representing a model of oncogene addiction (53). Additionally, kinase 
domain mutations render the EGFR extremely sensitive to small molecule EGFR 
TKIs, which compete with ATP to reversibly bind to the kinase domain of mutant 
EGFR and inhibit the functioning of mutant EGFR (53). Due to shutting down of 
mutant EGFR with EGFR TKIs, NSCLCs undergo oncogene crisis and a significant 
regression in tumor size is observed in patients with EGFR mutant NSCLC (53).  As 
a result, the approval of small molecule EGFR TKIs for treatment of EGFR mutant 
NSCLC was very well acclaimed although the limitations of their efficacy due to 
development of drug resistance have become readily apparent (51, 52, 56) 
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Figure 1. Gefitinib and erlotinib sensitizing kinase domain mutations of 
EGFR in NSCLC. A representation of epidermal growth factor receptor (EGFR) 
showing the distribution of exons in extracellular domain (EGF binding), 
transmembrane domain (TM) and intracellular region comprising the tyrosine 
kinase and autophosphorylation domains. Exons 18–21 in the tyrosine kinase 
region where the relevant mutations are located are expanded (represented by the 
cyan bar), and a detailed list of EGFR mutations in these exons that are associated 
with sensitivity (magenta boxes) or resistance (yellow boxes) to gefitinib or erlotinib 
is shown. Sharma et al. Nature Reviews Cancer 7, 169–181 (March 2007) | doi: 
10.1038/nrc2088(53). 
 
Mechanisms of EGFR TKI resistance 
 Most NSCLCs with EGFR mutations achieve a marked response to treatment 
with EGFR TKIs gefitinib or erlotinib. However, despite this initial dramatic response 
of EGFR mutant tumors to EGFR TKIs, acquired resistance develops within few 
months of treatment (51, 52, 56). In an effort to understand the mechanisms 
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underscoring acquisition of drug resistance, Sequist and colleagues undertook a 
comprehensive genetic and histological analysis of 37 NSCLC patients in 2011 (57). 
All of the 37 patients had activating EGFR mutations; 54% of the patients had exon 
19 deletion mutation and 41% had the exon 21 L858R substitution mutation and had 
responded clinically to either gefitinib or erlotinib but subsequently developed 
resistance to EGFR TKIs (57). Tumor tissues were collected both before and after 
EGFR TKI treatment and were analyzed for the presence of genetic alterations 
using a clinical genotyping platform, the SNaPshot assay (57). They reported that 
about 49% patients acquired a second site T790M mutation in exon 20 of EGFR, 
which has been associated with acquired resistance to gefitinib and erlotinib (48, 
52). 5% patients developed MET amplification resulting into overexpression of Met 
receptor tyrosine kinase, which activates downstream intracellular signaling 
independent of EGFR, facilitating cancer cell survival. Other mechanisms of 
acquired drug resistance reported by this study were mutations in 
phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha (PIK3CA) 
gene (5%), EGFR amplification (8%) and transformation to SCLC (14%). However, 
resistance mechanisms for the remaining 30% of the patients remained elusive. The 
study reported that approximately half of the remaining 30% of these EGFR TKI 
resistant NSCLCs present with an epithelial to mesenchymal transition (EMT) 
phenotype (57).  
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Epithelial to mesenchymal transition  
 An epithelial to mesenchymal transition (EMT) is a critical development 
process where a polarized epithelial cell, which normally interacts with basement 
membrane via its basal surface, undergoes multiple biochemical changes that 
enable it to assume a mesenchymal cell phenotype, which includes enhanced 
migratory capacity, invasiveness, elevated resistance to apoptosis, and greatly 
increased production of extracellular matrix (ECM) components (58). The 
completion of an EMT is signaled by the degradation of underlying basement 
membrane and the formation of a mesenchymal cell that can migrate away from the 
epithelial layer in which it originated.  
 The molecular hallmarks of EMT are loss of epithelial traits such as adhesion 
protein E-cadherin, tight junction protein ZO-1 and upregulation of canonical 
mesenchymal proteins N-cadherin and Vimentin (59). Multiple signaling changes 
can induce EMT and all these signaling changes converge at transcription factors. 
EMT is induced and regulated by transcriptional reprogramming via transcription 
factors such as SNAIL, SLUG, ZEB-1 and TWIST (59, 60). 
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Regulation of EMT 
 EMT process can be controlled by intrinsic oncogenic activation, such as 
KRAS mutation (62) or Her2 overexpression (63). EMT can also be triggered by 
external stimuli from microenvironment, which is composed of the extracellular 
matrix (such as collagen and hyaluronic acid), cancer-associated fibroblasts, 
immune cells and many secreted soluble factors such as Wnt ligands including 
Wnt3A, Wnt5A, Wnt5B, Wnt6 or Wnt10A, transforming growth factor-β (TGF-β), 
hedgehog, epidermal growth factor, hepatocyte growth factor and cytokines such as 
tumor necrosis factor-α, interleukin-6 (Figure 3)(64). These growth factors or 
inflammatory cytokines can exert their effects in autocrine or paracrine manners. In 
addition, hypoxic environment can also induce EMT of cancer cells (65). Cell-cell 
interaction, such as Notch signal is another mechanism to trigger EMT process 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Epithelial to mesenchymal transition. A process by which epithelial 
cells lose their cell polarity and cell-cell adhesion, and gain migratory and invasive 
properties to become mesenchymal cells along with down regulation of E-
cadherin and upregulation of N-cadherin and vimentin proteins. Modified from 
Claudia Palena et al. Experimental Biology and Medicine (Maywood) 2011 236: 
537 DOI: 10.1258/ebm.2011.010367 (61). 
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(Figure 3)(64, 65). Interactions between the cancer cells and other local 
inflammatory cells or stromal cells may play an important role in the induction of 
EMT. Besides, intracellular cross talk between these EMT signaling pathways make 
the regulation of EMT more complex. Recent findings exemplify how the complex 
interplay between extra- and intracellular signals can trigger EMT and cancer 
progression (66). These signaling pathways orchestrate an elaborate gene program 
and protein network needed for the establishment of mesenchymal phenotypes. 
 
EMT in cancer progression 
 While EMT is a critical process during development and wound healing, 
recently properties of EMT have been implicated in human pathology, including 
fibrosis and cancer metastasis (59, 67). Not surprisingly, many of the same signaling 
pathways and transcription factors important to physiologic instances of EMT are 
also activated during pathologic EMT (59). The association of EMT and cancer 
progression has been revealed in several types of cancer including breast cancer, 
prostate cancer, pancreatic cancer and hepatoma (68, 69). Detailed analyses of 
tumor biopsies of NSCLC patients have revealed EMT phenotype in a number of 
EGFR TKI resistant tumors (57). Circulating tumor cells of a subset of NSCLC 
patients showed mesenchymal phenotype suggesting a link between EMT and lung 
cancer progression (70). Additionally, in vitro models of drug resistant EGFR mutant 
NSCLC are reported to have EMT phenotype (71). EMT has been reported to be a 
key step in progression of tumors towards metastasis and invasion (72). Moreover, 
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cancer cells undergoing an EMT have demonstrated increased resistance to 
apoptosis and chemotherapeutic drugs and to acquire traits reminiscent of those 
expressed by stem cells (73).  
 
EMT and drug resistance 
 A number of studies have shown that EMT plays a role in conferring 
resistance to cancer cells against conventional therapeutics (74). EMT has been 
reported to be a biomarker of de novo EGFR TKI resistance in a subset of head and 
neck carcinoma and lung carcinoma. (75, 76). Several studies have reported that 
human NSCLC cells containing wildtype EGFR show a variable sensitivity to EGFR 
TKI treatment in vitro and in vivo and the sensitivity of these cells and xenografts to 
EGFR TKI treatment can be predicted by whether the cells have undergone EMT or 
not (75, 76). Precisely, NSCLC with wildtype EGFR which were insensitive to EGFR 
TKI treatment showed evidences of EMT (75, 76). Ectopic expression of epithelial 
protein E-cadherin in NSCLC cells enhanced gefitinib sensitivity (77) which suggests 
that EMT contributes to resistance of EGFR TKIs. Although the relationship between 
EMT and drug resistance has been established, the mechanisms underlying drug 
resistance and EMT remain elusive. Recently, AXL receptor tyrosine kinase has 
been reported to be activated and is thought to be the regulator of drug resistance in 
EMT positive EGFR mutant NSCLC (78-80). Three independent studies 
investigating the role of AXL in acquired EGFR TKI resistance demonstrate strong 
correlation between mesenchymal phenotype and AXL activation, suggesting that 
17 
 
17 
 
AXL is capable of replacing the function of mutant EGFR in EGFR mutant NSCLC 
and breast cancer cells (78-80). Although these studies demonstrate that increased 
AXL expression and activation is associated with mesenchymal signature and drug 
resistance, none of these studies directly address the potential mechanisms 
underlying AXL upregulation.  
 
EMT transcription factors 
 Though the signaling pathways are complex, the hallmark of EMT in cancer is 
downregulation of E-cadherin, which is also thought to be a repressor of invasion 
and metastasis (59, 81). E-cadherin, encoded by human CDH1 gene is a cell–cell 
adhesion glycoprotein gene that participates in homotypic, calcium-dependent 
interactions to form epithelial adherene junctions and sequestrate β-catenin (81). 
Transcription factors promote or inhibit the transcription of a gene by binding to 
specific motifs on the DNA are implicated in the transcriptional repression of E-
cadherin (82). Several transcription factors that are reported to be playing a role in 
transcriptional repression of E-cadherin,  include zinc finger proteins SNAIL, SLUG, 
ZEB1, ZEB2/SIP1 as well as the basic helix loop-helix factors TWIST and E47 (82). 
These factors bind to specific sequences in the CDH1 promoter that contain a 
central core 5′-CACCTG-3′ and are denominated E-boxes. By binding to the E-
boxes, these transcriptional factors repress the transcription of CDH1 gene (82). 
These transcription factors can also suppress a subset of genes that encode 
cadherins, claudins, occludins, plakophilins, MUC1 and cytokeratins to induce EMT 
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(64, 73). Additionally, these transcription factors are capable of repressing the 
expression of pro-apoptotic genes such as PTEN, p53, Bid, PUMA and have been 
associated with resistance to radiotherapy, chemotherapy, endocrine therapy and 
targeted therapy (64, 73). These transcription factors promote the expression of 
genes including Sox 2, Nanog, KLF4 and T cell factor-4 that are required for the 
synthesis of stem cell markers such as aldehyde dehydrogenase 1 (73). Owing to 
the central role of transcription factors in promoting a mesenchymal, highly invasive 
and drug resistant phenotype to cancer cells, recently transcription factors are being 
explored as novel drug targets for treatment of resistant tumors (83). 
 
Transcription factors as drug targets 
 Upregulation of EMT inducing transcription factors has been reported in 
several carcinomas and has been considered to be a cause of drug resistance. 
Moreover ectopic overexpression of transcription factors SNAIL and SLUG has been 
reported to repress E-cadherin expression, induce mesenchymal phenotype and 
affect sensitivity to chemotherapeutic drugs (60, 84). Role of transcription factors is 
very well studied with respect to tumor metastasis (85) however, the mechanisms of 
action of EMT transcription factors with respect to resistance to EGFR TKIs is not 
well defined at present. In the context of NSCLC, the rationale for investigating if 
transcription factors induced EMT is a predictor of sensitivity to EGFR TKIs in EGFR 
mutant NSCLC is that EMT could be used as a biomarker to identify the patients 
that would not benefit from treatment with EGFR TKIs. Further if EMT is a 
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mechanism of acquired resistance to EGFR TKIs in EGFR mutant NSCLC, then 
targeting EMT regulators in order to prevent the induction of EMT or reversing 
mesenchymal phenotype could be developed as a novel therapy for EGFR TKI 
resistant EGFR mutant NSCLC. As evident from Figure 3, all the signaling cascades 
that can induce EMT mediate their actions via transcription factors. The 
overreaching goal of this study is to investigate the role of the transcription factor 
that acts as a regulator of EMT that can be further developed as a novel drug target 
to overcome resistance to EGFR TKIs in EGFR mutant NSCLC.  
 
Expression of transcription factors in EGFR mutant NSCLC 
 In order to investigate if induction of mesenchymal phenotype is sufficient to 
confer resistance to EGFR TKIs in EGFR mutant NSCLC, Dr. Shimamura previously 
developed in vitro model of EMT by chronic exposure of EGFR mutant HCC827 
NSCLC cell line to TGF-β (personal communication), since TGF-β is a potent 
inducer of EMT (86). HCC827 cells are epithelial cells that are exquisitely sensitive 
to EGFR TKIs due to exon 19 deletion mutation in kinase domain of EGFR. Chronic 
exposure of HCC827 cells to 10 ng/ml TGF-β for 30 days promotes EMT with 
downregulation of E-cadherin and upregulation of vimentin.  
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Figure 3. Multiple signaling cascades converge at EMT-inducing 
transcription factors. Several key cellular signal transduction pathways that 
promote EMT exert their effects via modulation of transcription factors including 
SNAIL, SLUG, and ZEB1. Intervention of upstream signaling pathways 
controlling EMT-inducing transcription factors is essential for delineating the 
strategies to prevent EMT and associated acquired EGFR TKI resistance. Yang 
et al. Developmental cell. Volume 14, Issue 6, 10 June 2008, Pages 818-829 
(87). 
 
 To identify genes uniquely modulated in the mesenchymal HCC827 cells 
exposed to TGF-β but not in parental HCC827 cells, gene expression profiling was 
performed by isolating total RNA from TGF-β treated and untreated cells in 
triplicates and cRNA was synthesized to hybridize to Human Genome Array U133A2 
chips following manufacturer’s instructions (Affymetrix, Inc).  Differences in signal 
intensity were normalized using robust multi-array (RMA) method utilized in 
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Genepattern. 91 EMT-related genes curated from literatures were selected and 
tested if they were significantly upregulated or downregulated in mesenchymal 
HCC827 cells using two-sided T-tests and selecting genes that changed more than 
3-fold (Figure 4), significant (p<0.05, fold change > 3) upregulation of EMT 
associated transcription factors, SNAI1 (SNAIL) and SNAI2 (SLUG) was observed in 
HCC827 cells exposed to TGF-β (Figure 4).  
 
  
 
 
 
 
 
 
 
 
 
 
Figure 4. EMT induced by chronic 
exposure of EGFR mutant NSCLC 
cells to TGF-β leads to increased 
expression of EMT inducing 
transcription factors. Differential gene 
expression profiling of TGF-β exposed 
mesenchymal HCC827 cells and 
parental epithelial HCC827 cells. Genes 
upregulated or downregulated 
significantly are shown (p<0.01 t-test, 
fold change>2). 
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Furthermore, HCC827 cells exposed to TGF-β and having high levels of SNAIL and 
SLUG were resistant to EGFR TKIs (Figure 5). Additionally, withdrawal of TGF-β 
from EMT positive HCC827 cells resulted in reversion to epithelial HCC827 cells 
that are equally sensitive to EGFR TKIs (Figure 5). This experiment suggested that 
induction of EMT confers resistance to EGFR TKIs in EGFR mutant NSCLC. 
 
 
 
Figure 5. EMT induced by chronic exposure of EGFR mutant NSCLC 
cells to TGF-β confers resistance to EGFR TKI gefitinib and erlotinib. 
HCC827 cells chronically exposed to 10 ng/ml TGF-β for 30 days were 
subjected to MTT cell viability assay with gefitinib for 72 hours.  
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Consequently, we hypothesized that the reversal of mesenchymal phenotype in 
EGFR mutant NSCLCs with EMT-mediated EGFR TKI acquired resistance to 
epithelial phenotype should resensitize the resistant cells to EGFR TKIs. To test this 
hypothesis, we turned our attention to transcription factors that induce EMT. 
Conditional expression of EMT inducing transcription factors in HCC827 cells might 
provide a novel platform to induce and reverse EMT and test to EGFR TKI 
sensitivity and reversibility of EMT mediated EGFR TKI resistance NSCLC. 
 As evident from Figure 4, EMT positive and EGFR TKI resistant HCC827 
cells generated by chronic exposure to TGF-β showed high levels of EMT inducing 
transcription factors SNAIL and SLUG. The role of transcription factor SLUG in 
NSCLC has been previously investigated and SLUG has been reported to be a 
metastasis promoting transcription factor which acts by upregulating matrix 
metalloproteinase-2 and increasing angiogenesis (85, 88). However the role of 
SLUG in regulating sensitivity to EGFR TKIs is still unclear. Transcription factor 
SNAIL is more potent than SLUG in repressing E-cadherin due in part to the higher 
affinity of SNAIL to the promoter region of E-cadherin (82). Additionally, previous 
findings from our laboratory and literatures suggest that transcription factor SNAIL 
acts directly downstream of TGF-β in mediating EMT by suppressing E-cadherin 
expression (Figure 4)(89, 90). Hence, to control epithelial and mesenchymal 
phenotypes in EGFR mutant NSCLC cells, we sought to stably and conditionally 
express SNAIL in EGFR mutant NSCLC cell line. Such an in vitro model of SNAIL 
overexpression will enable us to systematically evaluate the potential of transcription 
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factor SNAIL as a novel drug target for treatment of EGFR TKI resistant EGFR 
mutant NSCLC. 
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CHAPTER TWO 
PROJECT OVERVIEW 
Hypothesis 
 We hypothesize that overexpression of EMT transcription factor SNAIL 
induces mesenchymal phenotype and is sufficient to confer EGFR TKI resistance in 
EGFR mutant NSCLC. We further hypothesize that reversing the mesenchymal 
phenotype or promoting epithelial phenotype will resensitize EGFR mutant NSCLC 
to EGFR TKIs. 
 
Testing this hypothesis helps us answer the most clinically relevant question, if 
reversing EMT should be developed as a therapeutic target to overcome resistance 
to EGFR TKIs. The hypothesis will be tested by studies proposed in following two 
specific aims. 
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Specific Aims 
1: Determine if transcription factor SNAIL induces mesenchymal phenotype 
and confers EGFR TKI resistance in EGFR mutant NSCLC. 
1a. Ectopically overexpress SNAIL in EGFR mutant NSCLC cells to promote 
mesenchymal phenotype. 
1b. Determine if SNAIL overexpression is sufficient to confer resistance to EGFR 
TKIs. 
 
2: Determine if mesenchymal phenotype induced by transcription factor 
SNAIL is reversible and is sufficient to reverse SNAIL induced EGFR TKI 
resistance. 
2a. Establish and characterize EGFR mutant NSCLC cells with inducible expression 
of SNAIL. 
2b. Determine the reversibility of mesenchymal phenotype by conditional expression 
of SNAIL.  
2c. Determine if reversing mesenchymal phenotype by conditional expression of 
SNAIL is sufficient to restore sensitivity of EGFR mutant NSCLC to EGFR TKIs. 
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CHAPTER THREE 
MATERIALS AND METHODS 
Cell lines 
HCC827 NSCLC cell lines were obtained from American Type Culture Collection 
(ATCC). Stable GFP and SNAIL overexpressing HCC827 cells were cultured in 
RPMI 1640 supplemented with 5 % Fetal Bovine Serum (FBS) and 1 % antibiotic- 
antimycotic (AB/AM)(10,000 units/mL of penicillin, 10,000 µg/mL of streptomycin, 
and 25 µg/mL of Fungizone). HCC827 cells with inducible expression of GFP and 
SNAIL were cultured in RPMI 1640 supplemented with 5 % tetracycline free FBS 
and 1 % AB/AM. 293LTV cells were cultured in Dulbecco's Modified Eagle Medium 
(DMEM) supplemented with 10% FBS and 1 % ABAM. 293FT cells were maintained 
in complete medium containing 0.1 mM MEM non-essential amino acids, 4 mM L-
glutamine, 1 mM sodium pyruvate, 500 μg/mL Geneticin (G418), 10 % FBS and 1 % 
AB/AM. 
 
Generation of HCC827 cells stably overexpressing C-terminal V5-taggged 
SNAIL 
HCC827 cells with stable V5 tagged SNAIL expression were generated using PCR 
cloning system with Gateway® Technology with pDONR221 & OmniMax 2 
competent cells, Catalog number 123535-029 (Invitrogen, Carlsbad, CA). attB 
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SNAIL (gateway specific substrate) was generated by a Polymerase Chain Reaction 
(PCR). SNAIL sequence cloned into pBabe SNAIL retroviral plasmid (Addgene, 
Cambridge, MA) was amplified by PCR using AccuPrime® Taq DNA polymerase 
high fidelity enzyme (Invitrogen, Carlsbad, CA) and primers containing a 25-base 
pair attB sequence followed by SNAIL forward or reverse primer sequence (Table 
1). Further, using the gateway recombination cloning technology with Clonase II 
enzyme (Invitrogen, Carlsbad, CA), we subcloned attB SNAIL generated by PCR 
into entry vector pENTR304 (Addgene, Cambridge, MA) to generate entry clone 
pENTR304 SNAIL. In a consequent recombination reaction, pENTR304 SNAIL was 
subcloned into destination vector pEXP304 (Addgene, Cambridge, MA) which has a 
C-terminal V5 tag to generate expression clone pEXP304 SNAIL-V5. Entry clone for 
GFP - pENTR304 GFP (Addgene, Cambridge, MA) was subcloned into destination 
vector pEXP304 (Addgene, Cambridge, MA) to generate expression clone pEXP304 
GFP-V5. Subclones pENTR304 SNAIL, pENTR304 GFP, pEXP304 SNAIL-V5, 
pEXP304 GFP-V5 were verified by restriction digest and sequencing using Genewiz 
DNA sequencing services (South Plainfield, NJ). Lentivirus coding for SNAIL and 
GFP expression vectors were generated by transfection of 293LTV cells using 
TransIT® transfection reagent (MIRUS, Madison, WI).  HCC827 cells were infected 
with these lentiviruses in the presence of polybrene (10 μg/ml). 24 hours after 
infection, medium was replaced and cells were maintained in RPMI 1640 media 
supplemented with 5% Fetal Bovine Serum (FBS), 1 % (AB/AM) and blasticidin 20 
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µg/ml. Single cell colonies were isolated, expanded and screened for stable ectopic 
expression of SNAIL and GFP. 
 
 Table 1. SNAIL Primers 
Gene Primer Sequence Product 
size (bp) 
SNAIL 
 
Forward: 
GGGGACAAGTTTGTACAAAAAAGCAGGCTTCGAAGG
AGATAGAACCATGCCGCGCTCTTTCCTCGTCAGG 
 
Reverse: 
GGGGACCACTTTGTACAAGAAAGCTGGGTAGCGGG
GACATCCTGAGCAGCC 
800 
 
 
Generation of HCC827 cell line with inducible SNAIL overexpression 
Doxycycline inducible HCC827 SNAIL and GFP cell lines were generated by using 
ViraPower HiPerform T-REx Gateway® Expression System, Catalog number 
A11141 (Invitrogen, Carlsbad, CA). plenti 3.3/TR (tet repressor) vector was 
transfected into 293FT cells to generate lentivus coding for plenti 3.3tetR. HCC827 
cells were infected with lentivirus codings for plenti3.3/TR to generate HCC827tetR 
cell line with constitutive expression of tet repressor. Single cell colonies were 
isolated and screened for highest expression of tet repressor. SNAIL and GFP entry 
clones pENTR SNAIL and pENTR GFP respectively were subcloned into 
pLenti6.3/TO/V5-DEST plasmid vector using gateway recombination cloning 
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technology to generate expression vectors with components of tetracycline 
regulated (TET ON) system. Lentivirus coding for pLenti6.3/TO/V5-SNAIL and 
pLenti6.3/TO/V5-GFP were generated by transfection of 293FT cells using 
Lipofectamine® 2000 (Invitrogen, Carlsbad, CA). HCC827tetR (highest tet repressor 
expressing HCC827 clone) cells were infected with pLenti SNAIL-V5 and pLenti 
GFP-V5 lentiviruses in the presence of polybrene (10 μg/ml). 24 hours post 
infection, medium was replaced and cells were maintained in RPMI 1640 
supplemented with 5% Tetracycline free FBS, 1 % ABAM, G418 1000 µg/ml and 
blasticidin 20 µg/ml. Pooled stable cell lines were screened for the ability of 
doxycycline to induce relevant transgene expression. 
 
Drug treatments 
Gefitinib and XL-184 were purchased from ChemieTek (Indianapolis, IN). 17DMAG 
and AUY922 were purchased from LC laboratories (Woburn, MA). Stock solutions of 
drugs were prepared in dimethyl sulfoxide (DMSO) at a concentration of 10 mM and 
maintained at -20 °C. Drugs were diluted to 1 mM using DMSO for a working 
solution and used at concentrations ranging from 0.001 to 10 µM. 
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Western blot analysis 
 Whole cell lysates were prepared in lysis buffer containing 20 mM Tris-HCl (pH 7.5), 
150 mM NaCl, 1 mM Na2EDTA, 1 mM EGTA, 1 % Triton, 2.5 mM sodium 
pyrophosphate,1 mM beta-glycerophosphate,1 mM Na3VO4,1 µg/ml leupeptin (Cell 
Signaling Technology, Danvers, MA) supplemented with halt protease and 
phosphatase inhibitor cocktail containing AEBSF-HCl, aprotinin, bestatin, E-64, 
EDTA, leupeptin, pepstatin A (Pierce, Rockford, IL). Protein concentrations were 
determined using the bicinchoninic acid (BCA) protein assay kit (Pierce, Rockford, 
IL) and equivalent amounts (40 μg) of cell lysates were subjected to SDS-PAGE on 
4 % to 20 % gradient gels. V5 tag antibody was purchased from Invitrogen 
(Carlsbad, CA). Snail, E-cadherin, Vimentin, Claudin, Akt/pAkt, Erk/pErk, pEGFR, 
MET/pMET, HER3/pHER3 antibodies were purchased from Cell signaling 
technology (Danvers, MA). EGFR antibody was purchased from Santacruz 
Biotechnology (Dallas, TX) and tetR antibody was purchased from Boca Scientific 
Inc (Boca Raton, FL).  
 
Cell proliferation assay 
Cells were seeded at a density of 3,000 cells per well in 96-well plates and cultured 
in the presence of drugs alone or in combination for 72 hours. After 72 hours, cells 
were incubated at 37 °C in the presence of Cell Counting Kit-8 (CCK-8) (Dojindo 
Molecular Technologies Inc., Rockville, Maryland) reagent for 3-4 hours. CCK-8 
reagent is a highly water soluble tetrazolium salt which is reduced to a yellow 
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colored formazan dye by the activity of dehydrogenases in the cells. The amount of 
yellow formazan dye is directly proportional to the number of living cells which is 
estimated by measuring the optical density of cells at 450 nm. After incubation with 
CCK-8 reagent, optical density was measured at 450 nm by reading the plates using 
microplate reader (BioTek, Winooski, VT). Data were graphically displayed using 
GraphPad Prism version 5.00 for Windows (GraphPad Software, La Jolla, CA). The 
curves were fitted using a nonlinear regression model with a sigmoidal dose 
response. 
 
Crystal violet formaldehyde assay   
To account for the slower growth rate of mesenchymal HCC827 SNAIL-V5 CL7 as 
compared to HCC827 GFP cells (determined by growth curve analysis), HCC827 
SNAIL-V5 CL7 were seeded at a density twice that of HCC827 GFP cells. HCC827 
GFP (0.3X106 cells/well) and HCC827 SNAIL-V5 CL7 (0.6 X106   cells/well) were 
seeded in duplicates in 6 well plates. Cells were cultured either with DMSO or 1 µM 
EGFR TKI gefitinib for 72 hours. After 72 hours, cells were washed with 1 ml 
PBS(+/+) to remove dead cells and the cells attached to the plates were stained with 
2 ml crystal violet formaldehyde solution (0.05 %w/v crystal violet, 1% formaldehyde, 
1X PBS, 1% methanol). Crystal violet formaldehyde solution stains proteins of cells. 
The intensity of violet staining is directly proportional to the number of living cells 
attached to the plate.  
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Flow cytometric analysis of apoptosis  
0.3X106 cells/well HCC827 and HCC827 SNAIL-V5 CL7 were seeded in duplicates 
in a 6 well plate and allowed to adhere to the plate for 24 hours. Cells were cultured 
in the presence of either DMSO or gefitinib (1 µM) for 48 hours. After 48 hours cells 
were washed twice with cold cell staining buffer (Biolegend, San Diego, CA) and 
resuspended in annexin V binding buffer (Biolegend, San Diego, CA) at a 
concentration of 0.1X107 cells/ml. 100 µl of cell suspension was transferred to a 5 ml 
tube and stained with 10 µl FITC annexin V and 10 µl propidium iodide (PI) 
(Biolegend, San Diego, CA) for 30 minutes after which percentage apoptosis was 
determined by FACS analysis using BD canto II machine (BD Biosciences, San 
Jose, CA). Results were analyzed using Flowjo software (Tree Star Inc., Ashland, 
OR). 
 
Estimation of apoptosis by Poly ADP ribose polymerase cleavage 
0.3X106 cells were seeded in duplicates in 6-well plates and allowed to adhere to the 
plate for 24 hours. Cells were then treated with either DMSO or gefitinib (1 µM) for 
48 hours. After 48 hours whole cell lysates were prepared using lysis buffer 
containing SDS. Lysates were analyzed for percentage Poly ADP ribose polymerase 
(PARP) cleavage by 3-plex apoptosis assay using Luminex analyzer (Millipore, 
Danvers, MA). Luminex analyzer color-codes tiny beads, called microspheres, into 
500 distinct sets. Each bead set can be coated with a reagent specifically designed 
to quantify cleaved PARP (cleavage sites: aspartic acid 214 and glycine 215) in cell 
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lysate, allowing the capture and detection of cleaved PARP from the sample. The 
results are analyzed by xPONENT® v3.1 Software of the xMAP technology 
operating system (Millipore, Danvers, MA). β-actin was used to normalize the levels 
of PARP between different cell lines. 
 
Phospho-receptor tyrosine kinase proteome array 
1X106 cells were seeded in duplicates in 6-well plates and allowed to adhere to the 
plate for 24 hours. Cells were then treated with either DMSO or gefitinib (1 µM) for 
24 hours. After 24 hours cells whole cell lysates were prepared by solubilizing the 
cells at 1X107 cells/mL in receptor tyrosine kinase (RTK) array specific lysis buffer 
(R&D Systems, Minneapolis, MN). 100 µg of DMSO or gefitinib (1 μM) treated whole 
cell lysate were applied to each array and the array was developed following RTK 
array protocol (R&D systems Catalog # ARY001B).  
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CHAPTER FOUR 
RESULTS 
Ectopic SNAIL overexpression in EGFR mutant NSCLC: Transcription factor 
SNAIL is known to induce mesenchymal phenotype in cultured cells (82, 91). To 
systematically analyze the phenotypic changes associated with SNAIL expression 
we decided to generate an in vitro model of ectopic SNAIL overexpression in EGFR 
mutant NSCLC. We ectopically overexpressed SNAIL in EGFR mutant HCC827 
NSCLC cells and identified 2 subclones HCC827 SNAIL-V5 CL 7 and HCC827 
SNAIL-V5 CL 11 with highest ectopic expression of SNAIL (Figure 6). We next 
investigated if ectopic SNAIL overexpression is sufficient to induce an EMT in 
HCC827 SNAIL-V5 CL 7 and HCC827 SNAIL-V5 CL 11 cells. We observed that 
canonical epithelial marker E-cadherin is significantly downregulated whereas 
canonical mesenchymal marker vimentin is upregulated in HCC827 SNAIL-V5 CL11 
and HCC827 SNAIL-V5 CL7 as compared to HCC827 and HCC827 GFP cells 
(Figure 6). 
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Figure 6. Ectopic SNAIL overexpression in HCC827 cells promotes 
mesenchymal phenotype. Western blot analysis of HCC827, HCC827 GFP, 
HCC827 SNAIL-V5 clone (CL)-11 and HCC827 SNAIL-V5 clone (CL)-7. Whole 
cell lysates were resolved on SDS-PAGE and Western blot was performed 
using indicated antibodies. β-Actin serves as loading control. HCC827 shCDH1 
are cells with E-cadherin knockdown respectively. HCC827shNT serves as 
negative control for E-cadherin knockdown & serve as positive control for EMT 
markers. 
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Morphology of EGFR mutant NSCLC with ectopic SNAIL overexpression: Cells 
that transition into a mesenchymal state undergo morphological changes (59), 
hence we sought to investigate changes in cell shape and growth pattern in ectopic 
SNAIL overexpressing HCC827 cells. We observed that parental HCC827 and 
HCC827 GFP cells displayed the classic cobblestone epithelial morphology and 
tight cell-cell junctions of epithelial cells while HCC827 SNAIL-V5 CL7 and HCC827 
SNAIL-V5 CL11 HCC827 exhibited a fibroblastic morphology and assumed a 
scattered growth pattern (Figure 7). 
 
Ectopic SNAIL overexpression alters sensitivity of EGFR mutant NSCLC to 
EGFR TKI: Ectopic expression of EMT transcription factors has been reported to 
alter sensitivity of cancer cells to EGFR TKIs (84, 92), hence we investigated if 
ectopic SNAIL expression affects EGFR TKI sensitivity of EGFR mutant NSCLC. 
When investigated by crystal violet formaldehyde assay (Figure 8) we observed that 
either gefitinib or DMSO (vehicle) treatment in HCC827 SNAIL overexpressing cells 
did not compromise cell viability whereas gefitinib treatment in HCC827 GFP cells 
resulted in significant cell loss evidenced by absence of stained cells and significant 
percent control reduction in crystal violet staining (Figure 8). We estimated 
percentage apoptosis induced by gefitinib by flow cytometric analysis and observed 
that gefitinib treatment induced 2 fold more cell death in HCC827 cells (17.04 % 
apoptosis) when compared with DMSO treated HCC827 cells (9.91 % apoptosis) 
while there was no change in percentage apoptosis in HCC827 SNAIL 
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overexpressing cells treated with (6.17 % apoptosis) or without (6.8 % apoptosis)  
gefitinib. 
 
 
 
 
Figure 7. Morphological changes in HCC827 cells with ectopic SNAIL 
overexpression. Figure shows bright field microscopic images (4X 
magnification) which reveal flattened, fibroblastic morphology & scattered growth 
pattern of HCC827 SNAIL-V5 CL7 & HCC827 SNAIL-V5 CL11. 
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Figure 8. Gefitinib treatment does not compromise viability of cells ectopically 
expressing SNAIL-V5. (A) HCC827 GFP cells (0.3x106 cells/well) and 
HCC82SNAIL-V5 CL7 (0.6x106 cells/well) were seeded in 6 well plate and allowed 
to adhere to the plate for 24 hours, after which cells were treated with DMSO or 1 
µM gefitinib for 72 hours. After 72 hours cells were washed with PBS (+/+) to 
remove dead cells and then stained with crystal violet formaldehyde solution. 
Intensity of violet color produced after staining with crystal violet is proportional to 
number of viable cells. Gefitinib or DMSO treatment in HCC827 SNAIL-V5 CL7 cells 
did not compromise cell viability whereas gefitinib treatment in HCC827 GFP cells 
compromised cell viability as evidenced by absence of violet staining. (B) 
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Quantification of crystal violet staining indicates that gefitinib treatment results in 85 
% control reduction in crystal violet staining of HCC827 GFP cells whereas only 15 
% control decrease in staining of HCC827 SNAIL 7. Results shown here are 
representative of 2 independent experiments analyzed in duplicates. Error bars 
indicate standard deviation. (C) Flow cytometric analysis using annexin V-FITC and 
propidium iodide staining indicates that 48 hours of 1 µM gefitinib treatment does not 
induce apoptosis in SNAIL overexpressing HCC827 cells. 
 
 
Ectopic SNAIL overexpressing EGFR mutant NSCLC cells are resistant to 
EGFR TKI induced apoptosis: EGFR TKIs are known to induce marked apoptosis 
in EGFR mutant NSCLC (55). Cancer cells with EMT phenotype are resistant to 
apoptosis induced by chemotherapeutic agents including cisplatin, paclitaxel (93, 
94). We investigated if mesenchymal phenotype associated with ectopic SNAIL 
expression inhibits EGFR TKI induced apoptosis in EGFR mutant NSCLC. We 
determined the levels of PARP cleavage induced by gefitinib treatment in HCC827 
cells with SNAIL overexpression and observed that gefitinib induced apoptosis is 
attenuated on ectopic SNAIL overexpression in HCC827 cells (Figure 9).  
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Attenuated EGFR, HER3 and MET receptor signaling in SNAIL overexpressing 
EGFR mutant NSCLC: In response to mesenchymal transition, cancer cells shift 
cellular equilibrium to rely on alternate growth factors and signaling receptors (95, 
96). Increased activation of MET and HER3 receptors has been reported in several 
lung cancer specimen that developed resistance to EGFR TKIs (97, 98). We 
investigated if ectopic SNAIL overexpression altered the expression and activation 
Figure 9. Gefitinib treatment does not induce apoptosis in SNAIL 
overexpressing EGFR mutant NSCLC. 0.3 x106 cells/well were seeded in 
duplicates in 6 well plate, allowed to adhere to plate for 24 hours and 
treated with DMSO or gefitinib (1 µM) for 48 hours. After 48 hours, whole 
cell lysate were prepared using lysis buffer containing SDS and lysates 
were analyzed for percentage PARP cleavage using 3-plex luminex assay. 
β-Actin was analyzed to normalize PARP levels between different cell lines. 
Error bars indicate standard deviation. 
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of MET or HER3 receptors in EGFR mutant NSCLC. We observed that EGFR, 
HER3 and MET receptors are downregulated and their activation is decreased in 
HCC827 SNAIL-V5 CL7 as compared to HCC827 GFP cells (Figure10). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10. Ectopic SNAIL over-expression promotes downregulation of 
EGFR, MET & HER3 expression. Western blot analysis indicated a 
decrease in both expression and activation of EGFR, MET & HER3 
receptors on ectopic SNAIL overexpression in HCC827 cells. β-Actin was 
analyzed as a loading control. 
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None of the known 42 receptor tyrosine kinases seem to be the driver of drug 
resistance in SNAIL overexpressing EGFR mutant NSCLC: Aberrant activation 
of several receptor tyrosine kinases has been reported to be sufficient to confer 
EGFR TKI resistance and drive the survival of carcinoma cells (99, 100). To 
examine if EGFR TKI resistant SNAIL overexpressing EGFR mutant NSCLC have 
increased activation of either known or potential novel driver of drug resistance 
which is capable of replacing function of mutant EGFR (96), we performed a RTK 
array analysis of HCC827 GFP and HCC827 SNAIL7 cells with or without treatment 
with gefitinib. The analysis did not identify the activation of HER3, MET, IGF-1R or 
any other well-known driver of drug resistance in EGFR mutant NSCLC (Figure 11). 
We observed increased activation of AXL in HCC827 SNAIL7 cells treated with 
DMSO, however the phosphorylation of AXL is lost upon treatment of HCC827 
SNAIL7 cells with gefitinib (1 µM) (Figure 11). 
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Figure 11. RTK array failed to identify a RTK that could be 
potentially activating cell survival and proliferation signals in EGFR 
TKI treated SNAIL overexpressing HCC827 cells. HCC827 cells 
expressing GFP or SNAIL7 were treated with either DMSO or gefitinib (1 
µM) for 24 hours after which whole cell lysates were subjected to RTK 
profiling. Each RTK is assayed in duplicates. The dots represent 
activated receptor tyrosine kinase. 
 
 
Ectopic SNAIL expressing EGFR mutant NSCLC cells are insensitive to AXL 
inhibitor XL-184: Activation of AXL receptor tyrosine kinase has been reported to 
be a mechanism of drug resistance in a subset of EMT positive EGFR mutant 
NSCLC (78-80). Furthermore, our RTK analysis showed activation of AXL receptor 
in SNAIL overexpressing HCC827 cells although the activation of AXL was inhibited 
on treatment with EGFR TKI gefitinib (Figure 11). To investigate if the survival of 
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mesenchymal EGFR mutant NSCLC is dependent on AXL activation, we treated 
HCC827 SNAIL overexpressing cells with AXL inhibitor XL-184 alone or in 
combination with gefitinib and determined percent control viability of the cells after 
72 hours of drug treatment. XL-184 is a compound that was originally developed as 
a VEGFR2 inhibitor but is also reported to inhibit AXL receptor with the IC50 being 7 
nM for Axl. XL-184 alone or in combination with gefitinib did not compromise viability 
of HCC827 SNAIL7 cells (Figure 12). 
 
 
Pharmacological inhibition of EGFR does not deplete PI3K/AKT and 
RAS/RAF/MEK/ERK signals in SNAIL overexpressing EGFR mutant NSCLC: 
PI3K/AKT and RAS/RAF/MEK/ERK signaling pathways have been shown to 
 
 
 
 
 
Figure 12. AXL inhibitor does not block the proliferation of HCC827 
SNAIL7. Exponentially growing HCC827 GFP and SNAIL7 cells were treated 
with indicated concentrations of gefitinib, XL-184 and a combination of both the 
drugs. At 72 hours, CCK-8 assay was performed and the viability of each sample 
was normalized to that of DMSO treated cells. 
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cooperate to promote cell survival and proliferation on NSCLC (101). A number of 
receptor tyrosine kinases such as EGFR, HER2, HER3, IGF-1R, PDGFR activate 
cell survival and proliferation signals (96). Surprisingly, none of the known potential 
drivers of cell survival and proliferation were activated in HCC827 SNAIL7 cells 
(Figures 10 and 11), yet SNAIL overexpressing HCC827 cells were resistant to 
treatment with EGFR TKI (Figures 8, 9 and 12) hence we decided to investigate 
whether or not cell survival and proliferation signals are still active in HCC827 
SNAIL7 cells treated with gefitinib. We observed that even after 48 hours of 
treatment with gefitinib (1 µM), PI3K/AKT and RAS/RAF/MEK/ERK  pathways are 
active in HCC827 SNAIL7 cells while these pathways are inhibited on gefitinib (1 
µM) treatment of HCC827 GFP cells (Figure 13).  
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Figure 13.  SNAIL overexpressing HCC827 cells retains cell 
survival and proliferation signals upon EGFR inhibitor 
treatment. Exponentially growing HCC827 GFP and SNAIL7 cells 
were cultured in the presence of DMSO or gefitinib (1 µM) for 48 
hours after which whole cell lysates were subjected to Western 
blotting using indicated antibodies. Sustained activation of Erk and 
Akt signals was observed in HCC827 SNAIL7 cells even after 48 
hours of gefitinib treatment while gefitinib treatment inhibited Erk 
and Akt phosphorylation in HCC827 GFP cells. GAPDH was 
assessed as loading control. 
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SNAIL overexpressing EGFR mutant NSCLC cells are sensitive to 
chemotherapeutic agents: EMT induced by transcription factors SNAIL and SLUG 
has been associated with chemo-resistance in ovarian cancer due to altered 
expression of genes involved in cell cycle regulation and drug transport (84). We 
investigated if ectopic SNAIL overexpression in EGFR mutant NSCLC renders the 
cells resistant to chemotherapeutic agents in general or if it is an EGFR TKI specific 
resistance mechanism.  HCC827 GFP and SNAIL7 cells were treated for 72 hours 
with 4 different concentrations of a chemotherapeutic agent gemcitabine which is a 
nucleoside analog known to arrest tumor growth and induce apoptosis in a number 
of cancers (102). We observed that both HCC827 SNAIL7 and HCC827 GFP cells 
were equally sensitive to 72 hours of treatment with gemcitabine, indicating that 
ectopic SNAIL overexpression does not affect sensitivity of EGFR mutant NSCLC to 
chemotherapeutic agents (Figure 14).  
 
 
 
 
 
 
 
 
 
50 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
A 
51 
 
 
B 
 
 
 
Figure 14. Gemcitabine induces apoptosis in SNAIL overexpressing EGFR 
mutant NSCLC. (A) Exponentially growing HCC827 GFP cells and HCC827 
SNAIL-V5 CL7 cells were seeded at 0.3 x106 cells/well in 6 well plate and allowed 
to adhere to the plate for 24 hours, after which cells were treated with indicated 
dose of gemcitabine for 72 hours. Effect of gemcitabine (GEM) treatment on cell 
viability was assessed by staining with crystal violet formaldehyde solution. (B) 
Quantification of crystal violet staining post gemcitabine treatment indicates 
significant reduction in percent control staining of HCC827 GFP as well as 
SNAIL7 cells. This suggests that gemcitabine treatment compromised cell viability 
of both HCC827 GFP and SNAIL7 cells. Results shown here are representative of 
two independent experiments analyzed in duplicates. Error bars indicate standard 
deviation.  
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Inducible SNAIL expression controls the expression of EMT markers and 
reversal of EMT in EGFR mutant NSCLC: EMT in theory is a reversible process 
(59), so we wanted to determine if EMT induced by ectopic SNAIL overexpression 
in EGFR mutant NSCLC is reversible. We developed doxycycline inducible GFP 
and doxycycline inducible SNAIL expressing HCC827 cell lines. We observed GFP 
expression after days of doxycycline treatment of HCC827 cells expressing 
inducible GFP vector (Figure 15A). Further expression of GFP was repressed after 
10 days of doxycycline removal from culture media of cells, indicating that gene 
expression is under doxycycline control (Figure 15A). After 10 days of doxycycline 
induced SNAIL expression in HCC827 cells expressing inducible SNAIL vector, 
epithelial markers E-cadherin, claudin were downregulated and mesenchymal 
marker vimentin was upregulated (Figure 15B). After 10 days of removal of 
doxycycline from the cell culture media, the expression of SNAIL was inhibited, 
expression of epithelial markers E-cadherin, claudin was restored and 
mesenchymal marker vimentin was downregulated (Figure 15B).  
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Figure 15. Conditional expression of GFP and SNAIL in EGFR mutant NSCLC. 
(A) A representative image of HCC827 cells expressing inducible GFP vector. 
Expression levels of GFP in HCC827 lenti GFP cells changed as expected, on 
treatment of cells with or without doxycycline. (B) Western blot analysis of EMT 
markers in HCC827 cells with inducible SNAIL expression. HCC827 cells 
expressing inducible SNAIL vector were treated with or without doxycycline (1 
µg/ml) for the indicated time after which whole cell lysates were immunoblotted with 
antibodies against SNAIL, E-cadherin, vimentin and claudin. β-Actin serves as 
loading control. 
 
(A) (B) 
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Inducible SNAIL expressing EGFR mutant NSCLC are sensitive to EGFR TKI 
after 10 days of doxycycline induced SNAIL expression: Mesenchymal EGFR 
mutant NSCLCs with stable SNAIL expression are resistant to EGFR TKI (Figures 8 
and 9), therfore we investigated if inducible SNAIL expression alters EGFR TKI 
sensitivity of EGFR mutant NSCLC. When investigated by crystal violet viability 
assay, we observed that gefitinib treatment resulted in significant cell loss in 
inducible SNAIL expressing HCC827 cells treated with and without doxycycline for 
10 days as evidenced by absence of stained cells (Figure 16).  
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Figure 16. 10 days of doxycycline induced SNAIL expression is not sufficient to 
confer EGFR TKI resistance in EGFR mutant NSCLC. Inducible SNAIL expressing 
HCC827 cells, treated with or without doxycycline (1 µg/ml) for 10 days were 
seeded at a density of 0.3x106 cells/well in duplicates in 6 well plate and allowed 
to adhere to the plate for 24 hours, after which cells were treated with DMSO or 
1 µM gefitinib for 72 hours. After 72 hours, cells were washed with PBS (+/+) to 
remove dead cells and then stained with crystal violet formaldehyde solution. 
Intensity of violet color produced after staining with crystal violet is proportional 
to number of viable cells. As evidenced by absence of crystal violet staining, 
gefitinib treatment compromised viability of inducible SNAIL expressing HCC827 
cells treated with and without doxycycline for 10 days. 
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CHAPTER FIVE 
DISCUSSION 
 Development of molecular targeted therapies provides a treatment option in 
addition to conventional cancer treatments. Molecular targeted drugs interfere with 
and block specific molecular pathways involved in cancer growth. However, the 
efficacy of the targeted therapies remains restricted to the cancer cells with 
oncogene addiction (103). Oncogene addiction refers to the phenomenon in which 
cancer cells that contain multiple genetic and epigenetic changes remain addicted to 
one or a few genes for both maintenance of the malignant phenotype and cell 
survival (53, 103). One such oncogene that has been extensively targeted for the 
treatment of NSCLC is mutant EGFR, which is effectively blocked by EGFR TKIs 
(11). However, the development of resistance to EGFR TKIs continues to be the 
major limitation in the treatment of EGFR mutant NSCLC (57). 
 Resistance to EGFR TKIs in several cancers including NSCLC has been 
associated with a loss of canonical epithelial protein E-cadherin, suggesting 
involvement of EMT in conferring EGFR TKI resistance (75, 76). Transcription 
factors SNAIL, SLUG, ZEB1 and TWIST that are potent repressors of E-cadherin 
are being extensively studied as potential therapeutic targets to overcome EMT 
associated drug resistance in a number of cancers (83, 92).  
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 SNAIL, a zinc finger protein functions as transcriptional repressor of E-
cadherin by binding to E-box elements of E-cadherin promoter region (82). TGF-β, a 
secreted protein is known to directly activate transcription factor SNAIL by the action 
of Smad2, Smad3 and Smad4 to induce an EMT (89). TGF-β through activation of 
transcription factor SNAIL represses E-cadherin expression and induces a 
mesenchymal phenotype (89). In line with this reports, our preliminary experiments 
indicated that chronic TGF-β exposure results in more than 2 fold increase in SNAIL 
expression in EGFR mutant NSCLC (Figure 4). Further, TGF-β exposed EGFR 
mutant NSCLC cells with high SNAIL expression revealed an EMT gene signature 
and were resistant to EGFR TKIs (Figures 4 and 5). These results suggest a direct 
link between TGF-β mediated SNAIL activation and EGFR TKI resistance.  
The role of transcription factor SNAIL with respect to EGFR TKI resistance in 
EGFR mutant NSCLC is less explored. To establish a link between expression of 
SNAIL and EGFR TKI sensitivity, we developed an in vitro model of stable ectopic 
SNAIL expression in HCC827 cells (EGFR TKI sensitive EGFR mutant NSCLC cell 
line). Investigation of ectopic SNAIL overexpressing subclones revealed that ectopic 
SNAIL expression was sufficient to alter the expression of canonical EMT markers 
and induce a mesenchymal phenotype in EGFR mutant NSCLC (Figures 6 and 7 ). 
This observation was in line with previous reports that ectopic SNAIL expression 
induces EMT in several carcinomas (104). One important characteristic of 
mesenchymal cells is resistance to apoptosis (59, 73). Moreover, ectopic expression 
of EMT transcription factors is known to alter drug sensitivity of cancer cells (84, 92). 
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We observed that ectopic SNAIL expression in HCC827 was sufficient to inhibit 
gefitinib (1 μM) induced apoptosis (Figures 8 and 9) suggesting that EMT induced 
by SNAIL alters the sensitivity of EGFR mutant NSCLC to EGFR TKIs.   
 Owing to the fact that EMT is a reversible process, we hypothesized that EMT 
induced by SNAIL in EGFR mutant NSCLC is reversible. Our goal was to test if 
reversing the mesenchymal phenotype induced by ectopic SNAIL expression would 
resensitize EGFR mutant NSCLC to EGFR TKIs. To investigate the reversibility of 
SNAIL induced EMT, we developed an in vitro model of HCC827 cells with 
doxycycline inducible (Dox On) SNAIL expression. We developed HCC827 cells 
with doxycycline inducible GFP expression as a control for inducible gene 
expression system and ensured that gene expression is under doxycycline control 
(Figure 15A).  Expression of SNAIL induced by treatment with doxycycline (1 μg/ml) 
for 10 days, caused EMT like changes in the phenotype of cells. Canonical epithelial 
markers E-cadherin and claudin were downregulated and canonical mesenchymal 
marker vimentin was upregulated after 10 days of doxycycline induced SNAIL 
expression (Figure 15B).  
 Our observations with stable SNAIL expression in HCC827 cells suggested 
that mesenchymal phenotype induced by SNAIL expression confers EGFR TKI 
resistance in EGFR mutant NSCLC (Figures 8 and 9). However after 10 days of 
doxycycline induced SNAIL expression, HCC827 cells remained sensitive following 
72 hours exposure to 1 μM gefitinib  (Figure 16).  One possible explanation for this 
would be that level of SNAIL expression achieved after 10 days of doxycycline 
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treatment is  sufficient to engage the cells into a mesenchymal state but insufficient 
to induce a complete EMT to render the cells resistant to EGFR TKIs. There is 
substantial evidence that SNAIL plays a prominent role in triggering EMT while 
activation of other EMT regulators including SLUG, ZEB1 or TWIST is essential in 
maintaining the mesenchymal phenotype (105). It is tempting to speculate that such 
a subsequent activation of other EMT regulators might be achieved over a period of 
culturing of HCC827 cells with stable ectopic SNAIL expression but this event is not 
recapitulated by the short term inducible SNAIL expression in HCC827 cells. Long-
term doxycycline exposure of HCC827 cells expressing inducible SNAIL vector 
might enable complete induction of EMT and render the cells resistant to EGFR 
TKIs.  
 Ectopic SNAIL overexpression has been shown to confer resistance to a 
number of chemotherapeutic agents including paclitaxel, camptothecin, doxorubucin 
and 5-Fluorouracil in various carcinomas (84, 106, 107). Based on these reports, we 
expected that ectopic SNAIL overexpressing EMT positive HCC827 cells would be 
resistant to chemotherapeutic agents. Surprisingly, SNAIL overexpressing HCC827 
cells were sensitive to chemotherapeutic agent gemcitabine (Figure 14) suggesting 
that SNAIL induced drug resistance is specific to EGFR TKIs.  
 Although a link between EMT induced by transcription factor SNAIL and drug 
resistance has been established, the mechanisms by which EMT confers 
insensitivity to EGFR TKIs are poorly understood. One mechanism explaining the 
survival of EGFR dependent NSCLC even in the absence of EGFR activation is 
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acquisition of alternate routes to activate PI3K/Akt and Ras/Raf/Mek/Erk pathways 
(95). EMT can promote the survival and proliferation of cancer cells by activation of 
alternate receptor tyrosine kinases including HER3, MET, PDGFR, IGF1-R that are 
capable of activating PI3K/Akt/ and Ras/Raf/Mek/Erk pathways (95, 96). Recently, 
upregulation of AXL receptor tyrosine kinase has been strongly linked to increased 
activation of PI3K/Akt/ and Ras/Raf/Mek/Erk pathways in EMT positive EGFR  TKI 
resistant models of NSCLC (78, 79). However, ectopic SNAIL overexpressing 
HCC827 cells did not show increased activation of any of the known promoter of 
cellular survival and proliferation (Figures 10 and 11). Further, treatment of SNAIL 
overexpressing  HCC827 cells with AXL inhibitor XL-184 (1 μM) for 72 hours did not 
compromise the viability of cells, suggesting that AXL is less likely to be regulating 
cell survival and proliferation of SNAIL overexpressing HCC827 cells (Figure 12). 
Additionally, 48 hours exposure of SNAIL overexpressing HCC827 cells to 1 μM  
gefitinib did not suppress phosphorylations of Akt and Erk (Figure 13 suggesting that 
novel receptor or non-receptor tyrosine kinase or G protein coupled receptor 
pathways are established in the HCC827 SNAIL overexpressing cells to offset the 
loss of  mutant EGFR induced activation of PI3K/Akt and Ras/Raf/Mek/Erk 
pathways, thereby acting as promoters of EGFR inhibitor resistance (Figure 17). 
Future studies designed to investigate this novel driver of cell survival and 
proliferation in SNAIL induced EMT model of EGFR mutant NSCLC could provide a 
potential drug target to treat resistant NSCLC. 
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Figure 17. A schematic of proposed mechanism of EGFR TKI resistance 
in EGFR mutant NSCLC. A novel receptor tyrosine kinase (RTK), G protein 
coupled receptor (GPCR) or non-RTK might be activating PI3K/Akt and 
Ras/Raf/Mek/Erk pathway to promote cell survival and proliferation even in the 
absence of EGFR activation. 
 
 Literatures suggest that TGF-β is a potent inducer of EMT that requires 
activation of transcription factor SNAIL to exert its effects (89, 108). EGFR mutant 
NSCLC cells induced to mesenchymal state by chronic exposure to TGF-β express 
high level of SNAIL and are insensitive to EGFR TKIs, suggesting that the biological 
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activities induced by the expression of SNAIL might affect drug sensitivity (Figures 4 
and 5). Interestingly, SNAIL knockdown in cisplatin resistant pancreatic cancers and 
gemcitabine resistant ovarian cancers has been shown to restore sensitivity of the 
cancer cells to cisplatin and gemcitabine  (93, 109). These evidences suggest that 
the inhibitors of SNAIL activity might prevent SNAIL-dependent mesenchymal 
transition to restore or gain cellular sensitivity to EGFR TKIs.  
 Due to the fact that transcription factors mediate their actions mostly through 
protein-protein interactions rather than enzymatic activities, they have been 
traditionally regarded as undruggable targets. Recently rigorous efforts are being 
undertaken to understand the mechanisms of action of transcription factors that 
would enable rational designing of drugs targeting transcription factors (110, 111) . 
A group of researchers have developed a novel SNAIL inhibitor GN-25 that was 
shown to suppress SNAIL and reverse SNAIL-induced mesenchymal phenotype to 
epithelial phenotype through genetic reprogramming of EMT genes (110).  Another 
group of researchers have reported targeted inactivation of SNAIL family 
transcription factors by use of novel Co(III) E-box conjugate (111). Co(III) E-box 
conjugate is a Schiff base compound that selectively inhibits transcription factors 
that harbor zinc finger domain and bind to E-boxes. Such a dual specificity of Co(III) 
E-box conjugate might allow for targeted SNAIL disruption with very few off target 
effects. Additionally, phosphorylation of SNAIL on serine residues 104 and 107 by 
glycogen synthase kinase-β (GSK3β) has been reported to unmask the nuclear 
export sequence facilitating nuclear exit and subsequent ubiquitination of SNAIL 
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(82). This action is counteracted by a small C-terminal domain phosphatase (SCP) 
that stabilizes SNAIL in the nucleus (82). Agents that might potentially 
phosphorylate SNAIL at serine residues 104 and 107 and target SNAIL towards 
ubiquitination or agents that might inhibit the activation of SCP could be developed 
as a way to prevent and inhibit SNAIL activation. Concomitant administration of 
EGFR TKIs and SNAIL inhibitors might serve as a preventive treatment for the 
induction of mesenchymal phenotype with EGFR TKI resistance  by retaining EGFR 
TKI sensitivity of epithelial EGFR mutant NSCLC. Furthermore, molecular 
chaperone Hsp90 has been reported to bind to and stabilize phosphorylated SNAIL 
in response to DNA damage (112).Consequently, destabilization of SNAIL by Hsp90 
inhibitors might reverse SNAIL-dependent mesenchymal phenotype back into 
epithelial phenotype, which could be sensitive to EGFR TKIs. Taken together, our 
data suggests that development of drugs targeting transcription factor SNAIL is a 
promising strategy in overcoming EGFR TKI resistance and enhancing the efficacy 
of molecular targeted therapy in EGFR mutant NSCLC. 
 
 
64 
 
 
REFERENCES 
1. Jemal A, Siegel R, Xu J, Ward E. Cancer Statistics, 2010. 2010;60:277-300. 
Available from: 
http://onlinelibrary.wiley.com/doi/10.3322/caac.20073/abstract;jsessionid=9
351BDA706BBF189C2CD73D6C05C6724.d02t03. 
2. "Non-small cell lung cancer treatment (PDQ)-national cancer institute" 
[homepage on the Internet]. . 2013 03/20/2013. Available from: 
http://www.cancer.gov/CANCERTOPICS/PDQ/TREATMENT/NON-SMALL-
CELL-LUNG/PATIENT. 
3. Pal SK, Figlin RA, Reckamp K. Targeted therapies for non-small cell lung 
cancer: an evolving landscape. 2010;9(7):1931-44. 
4. "What is non-small cell lung cancer? american cancer society" [homepage on 
the Internet]. . 07/12/2013. Available from: 
http://www.cancer.org/cancer/lungcancer-non-smallcell/detailedguide/non-
small-cell-lung-cancer-what-is-non-small-cell-lung-cancer. 
5. Silvestri G. Chemotherapy for advanced lung cancer: is the glass half full or 
half empty? 2004;59(10):821. 
6. Ferrara N. Molecular and biological properties of vascular endothelial growth 
factor. 1999;77(7):527-43. 
7. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, 
Johnson DH. Paclitaxel-carboplatin alone or with bevacizumab for non-
small-cell lung cancer. 2006;355(24):2542-50. 
8. Herbst RS. Review of epidermal growth factor receptor biology. 2004;59(2 
Suppl):21-6. 
9. Arteaga CL. Epidermal growth factor receptor dependence in human tumors: 
more than just expression? 2002;7 Suppl 4:31-9. 
10. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. 
2001;2(2):127-37. 
65 
 
 
 
11. Ritter CA, Arteaga CL. The epidermal growth factor receptor-tyrosine kinase: 
a promising therapeutic target in solid tumors. 2003;30(1 Suppl 1):3-11. 
12. Salomon DS, Brandt R, Ciardiello F, Normanno N. Epidermal growth factor-
related peptides and their receptors in human malignancies. 
1995;19(3):183-232. 
13. Ellis PM, Morzycki W, Melosky B, Butts C, Hirsh V, Krasnoshtein F, Murray 
N, Shepherd FA, Soulieres D, Tsao MS, Goss G. The role of the epidermal 
growth factor receptor tyrosine kinase inhibitors as therapy for advanced, 
metastatic, and recurrent non-small-cell lung cancer: a Canadian national 
consensus statement. 2009;16(1):27-48. 
14. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, 
Thongprasert S, Campos D, Maoleekoonpiroj S, Smylie M, Martins R, van 
Kooten M, Dediu M, Findlay B, Tu D, Johnston D, Bezjak A, Clark G, 
Santabarbara P, Seymour L, National Cancer Institute of Canada Clinical 
Trials Group. Erlotinib in previously treated non-small-cell lung cancer. 
2005;353(2):123-32. 
15. Giaccone G, Herbst RS, Manegold C, Scagliotti G, Rosell R, Miller V, Natale 
RB, Schiller JH, Von Pawel J, Pluzanska A, Gatzemeier U, Grous J, Ochs 
JS, Averbuch SD, Wolf MK, Rennie P, Fandi A, Johnson DH. Gefitinib in 
combination with gemcitabine and cisplatin in advanced non-small-cell lung 
cancer: a phase III trial--INTACT 1. 2004;22(5):777-84. 
16. Herbst RS, Giaccone G, Schiller JH, Natale RB, Miller V, Manegold C, 
Scagliotti G, Rosell R, Oliff I, Reeves JA, Wolf MK, Krebs AD, Averbuch SD, 
Ochs JS, Grous J, Fandi A, Johnson DH. Gefitinib in combination with 
paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase 
III trial--INTACT 2. 2004;22(5):785-94. 
17. Tamura K, Fukuoka M. Gefitinib in non-small cell lung cancer. 2005;6(6):985-
93. 
18. Thienelt CD, Bunn PA,Jr, Hanna N, Rosenberg A, Needle MN, Long ME, 
Gustafson DL, Kelly K. Multicenter phase I/II study of cetuximab with 
paclitaxel and carboplatin in untreated patients with stage IV non-small-cell 
lung cancer. 2005;23(34):8786-93. 
19. Borghaei H, Langer CJ, Millenson M, Ruth KJ, Litwin S, Tuttle H, 
Seldomridge JS, Rovito M, Mintzer D, Cohen R, Treat J. Phase II study of 
66 
 
 
 
paclitaxel, carboplatin, and cetuximab as first line treatment, for patients 
with advanced non-small cell lung cancer (NSCLC): results of OPN-017. 
2008;3(11):1286-92. 
20. Lynch TJ, Patel T, Dreisbach L, McCleod M, Heim WJ, Hermann RC, 
Paschold E, Iannotti NO, Dakhil S, Gorton S, Pautret V, Weber MR, 
Woytowitz D. Cetuximab and first-line taxane/carboplatin chemotherapy in 
advanced non-small-cell lung cancer: results of the randomized multicenter 
phase III trial BMS099. 2010;28(6):911-7. 
21. Pirker R, Pereira JR, Szczesna A, von Pawel J, Krzakowski M, Ramlau R, 
Vynnychenko I, Park K, Yu CT, Ganul V, Roh JK, Bajetta E, O'Byrne K, de 
Marinis F, Eberhardt W, Goddemeier T, Emig M, Gatzemeier U, FLEX 
Study Team. Cetuximab plus chemotherapy in patients with advanced non-
small-cell lung cancer (FLEX): an open-label randomised phase III trial. 
2009;373(9674):1525-31. 
22. Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, Fujiwara 
S, Watanabe H, Kurashina K, Hatanaka H, Bando M, Ohno S, Ishikawa Y, 
Aburatani H, Niki T, Sohara Y, Sugiyama Y, Mano H. Identification of the 
transforming EML4-ALK fusion gene in non-small-cell lung cancer. 
2007;448(7153):561-6. 
23. FDA approves xalkori with companion diagnostic for a type of late-stage lung 
cancer [homepage on the Internet]. U.S. Food and Drug Aug. 26, 2011. 
Available from: 
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm2698
56.htm. 
24. Shaw AT, Kim DW, Nakagawa K, Seto T, Crino L, Ahn MJ, De Pas T, Besse 
B, Solomon BJ, Blackhall F, Wu YL, Thomas M, O'Byrne KJ, Moro-Sibilot D, 
Camidge DR, Mok T, Hirsh V, Riely GJ, Iyer S, Tassell V, Polli A, Wilner 
KD, Janne PA. Crizotinib versus chemotherapy in advanced ALK-positive 
lung cancer. 2013;368(25):2385-94. 
25. Zhang S, Wang F, Keats J, Zhu X, Ning Y, Wardwell SD, Moran L, 
Mohemmad QK, Anjum R, Wang Y, Narasimhan NI, Dalgarno D, 
Shakespeare WC, Miret JJ, Clackson T, Rivera VM. Crizotinib-resistant 
mutants of EML4-ALK identified through an accelerated mutagenesis 
screen. 2011;78(6):999-1005. 
67 
 
 
 
26. Choi YL, Soda M, Yamashita Y, Ueno T, Takashima J, Nakajima T, Yatabe 
Y, Takeuchi K, Hamada T, Haruta H, Ishikawa Y, Kimura H, Mitsudomi T, 
Tanio Y, Mano H, ALK Lung Cancer Study Group. EML4-ALK mutations in 
lung cancer that confer resistance to ALK inhibitors. 2010;363(18):1734-9. 
27. Orton RJ, Sturm OE, Vyshemirsky V, Calder M, Gilbert DR, Kolch W. 
Computational modelling of the receptor-tyrosine-kinase-activated MAPK 
pathway. 2005;392(Pt 2):249-61. 
28. Bos JL. The ras gene family and human carcinogenesis. 1988;195(3):255-71. 
29. Mascaux C, Iannino N, Martin B, Paesmans M, Berghmans T, Dusart M, 
Haller A, Lothaire P, Meert AP, Noel S, Lafitte JJ, Sculier JP. The role of 
RAS oncogene in survival of patients with lung cancer: a systematic review 
of the literature with meta-analysis. 2005;92(1):131-9. 
30. Isobe T, Herbst RS, Onn A. Current management of advanced non-small cell 
lung cancer: targeted therapy. 2005;32(3):315-28. 
31. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, 
Kaye FJ, Lindeman N, Boggon TJ, Naoki K, Sasaki H, Fujii Y, Eck MJ, 
Sellers WR, Johnson BE, Meyerson M. EGFR mutations in lung cancer: 
correlation with clinical response to gefitinib therapy. 2004;304(5676):1497-
500. 
32. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan 
BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani 
DC, Settleman J, Haber DA. Activating mutations in the epidermal growth 
factor receptor underlying responsiveness of non-small-cell lung cancer to 
gefitinib. 2004;350(21):2129-39. 
33. Wang D, Boerner SA, Winkler JD, LoRusso PM. Clinical experience of MEK 
inhibitors in cancer therapy. 2007;1773(8):1248-55. 
34. Lorusso PM, Adjei AA, Varterasian M, Gadgeel S, Reid J, Mitchell DY, 
Hanson L, DeLuca P, Bruzek L, Piens J, Asbury P, Van Becelaere K, 
Herrera R, Sebolt-Leopold J, Meyer MB. Phase I and pharmacodynamic 
study of the oral MEK inhibitor CI-1040 in patients with advanced 
malignancies. 2005;23(23):5281-93. 
35. Hainsworth JD, Cebotaru CL, Kanarev V, Ciuleanu TE, Damyanov D, Stella 
P, Ganchev H, Pover G, Morris C, Tzekova V. A phase II, open-label, 
68 
 
 
 
randomized study to assess the efficacy and safety of AZD6244 (ARRY-
142886) versus pemetrexed in patients with non-small cell lung cancer who 
have failed one or two prior chemotherapeutic regimens. 2010;5(10):1630-
6. 
36. Haura EB, Ricart AD, Larson TG, Stella PJ, Bazhenova L, Miller VA, Cohen 
RB, Eisenberg PD, Selaru P, Wilner KD, Gadgeel SM. A phase II study of 
PD-0325901, an oral MEK inhibitor, in previously treated patients with 
advanced non-small cell lung cancer. 2010;16(8):2450-7. 
37. Vivanco I, Sawyers CL. The phosphatidylinositol 3-Kinase AKT pathway in 
human cancer. 2002;2(7):489-501. 
38. Kawano O, Sasaki H, Endo K, Suzuki E, Haneda H, Yukiue H, Kobayashi Y, 
Yano M, Fujii Y. PIK3CA mutation status in Japanese lung cancer patients. 
2006;54(2):209-15. 
39. BEZ235 in combination with everolimus for advanced solid malignancies: 
Preliminary results of a phase ib dose-escalation study.[homepage on the 
Internet]. . 2013. Available from: 
http://meetinglibrary.asco.org/content/114177-132. 
40. Pearl LH, Prodromou C. Structure and in vivo function of Hsp90. 
2000;10(1):46-51. 
41. Pratt WB. The hsp90-based chaperone system: involvement in signal 
transduction from a variety of hormone and growth factor receptors. 
1998;217(4):420-34. 
42. Shimamura T, Perera SA, Foley KP, Sang J, Rodig SJ, Inoue T, Chen L, Li 
D, Carretero J, Li YC, Sinha P, Carey CD, Borgman CL, Jimenez JP, 
Meyerson M, Ying W, Barsoum J, Wong KK, Shapiro GI. Ganetespib (STA-
9090), a nongeldanamycin HSP90 inhibitor, has potent antitumor activity in 
in vitro and in vivo models of non-small cell lung cancer. 2012;18(18):4973-
85. 
43. Shimamura T, Lowell AM, Engelman JA, Shapiro GI. Epidermal growth factor 
receptors harboring kinase domain mutations associate with the heat shock 
protein 90 chaperone and are destabilized following exposure to 
geldanamycins. 2005;65(14):6401-8. 
69 
 
 
 
44. Antimetastatic activity of ganetespib: Preclinical studies and assessment of 
progressions due to new lesions in the GALAXY-1 NSCLC trial. [homepage 
on the Internet]. . 2013. Available from: 
http://meetinglibrary.asco.org/content/116799-132. 
45. A phase 3 study of ganetespib in combination with docetaxel versus 
docetaxel alone in patients with advanced NSCLC (Galaxy 2) [homepage 
on the Internet]. . 2013. Available from: 
http://clinicaltrials.gov/ct2/show/NCT01798485?term=galaxy&rank=4. 
46. Rusch V, Baselga J, Cordon-Cardo C, Orazem J, Zaman M, Hoda S, 
McIntosh J, Kurie J, Dmitrovsky E. Differential expression of the epidermal 
growth factor receptor and its ligands in primary non-small cell lung cancers 
and adjacent benign lung. 1993;53(10 Suppl):2379-85. 
47. Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, Douillard JY, 
Nishiwaki Y, Vansteenkiste J, Kudoh S, Rischin D, Eek R, Horai T, Noda K, 
Takata I, Smit E, Averbuch S, Macleod A, Feyereislova A, Dong RP, 
Baselga J. Multi-institutional randomized phase II trial of gefitinib for 
previously treated patients with advanced non-small-cell lung cancer (The 
IDEAL 1 Trial) [corrected. 2003;21(12):2237-46. 
48. Kosaka T, Yatabe Y, Endoh H, Kuwano H, Takahashi T, Mitsudomi T. 
Mutations of the epidermal growth factor receptor gene in lung cancer: 
biological and clinical implications. 2004;64(24):8919-23. 
49. Shigematsu H, Lin L, Takahashi T, Nomura M, Suzuki M, Wistuba II, Fong 
KM, Lee H, Toyooka S, Shimizu N, Fujisawa T, Feng Z, Roth JA, Herz J, 
Minna JD, Gazdar AF. Clinical and biological features associated with 
epidermal growth factor receptor gene mutations in lung cancers. 
2005;97(5):339-46. 
50. Janne PA, Engelman JA, Johnson BE. Epidermal growth factor receptor 
mutations in non-small-cell lung cancer: implications for treatment and 
tumor biology. 2005;23(14):3227-34. 
51. Pao W, Miller VA, Politi KA, Riely GJ, Somwar R, Zakowski MF, Kris MG, 
Varmus H. Acquired resistance of lung adenocarcinomas to gefitinib or 
erlotinib is associated with a second mutation in the EGFR kinase domain. 
2005;2(3):e73. 
70 
 
 
 
52. Kobayashi S, Boggon TJ, Dayaram T, Janne PA, Kocher O, Meyerson M, 
Johnson BE, Eck MJ, Tenen DG, Halmos B. EGFR mutation and resistance 
of non-small-cell lung cancer to gefitinib. 2005;352(8):786-92. 
53. Sharma SV, Bell DW, Settleman J, Haber DA. Epidermal growth factor 
receptor mutations in lung cancer. 2007;7(3):169-81. 
54. Sordella R, Bell DW, Haber DA, Settleman J. Gefitinib-sensitizing EGFR 
mutations in lung cancer activate anti-apoptotic pathways. 
2004;305(5687):1163-7. 
55. Jiang J, Greulich H, Janne PA, Sellers WR, Meyerson M, Griffin JD. 
Epidermal growth factor-independent transformation of Ba/F3 cells with 
cancer-derived epidermal growth factor receptor mutants induces gefitinib-
sensitive cell cycle progression. 2005;65(19):8968-74. 
56. Blackhall F, Ranson M, Thatcher N. Where next for gefitinib in patients with 
lung cancer? 2006;7(6):499-507. 
57. Sequist LV, Waltman BA, Dias-Santagata D, Digumarthy S, Turke AB, Fidias 
P, Bergethon K, Shaw AT, Gettinger S, Cosper AK, Akhavanfard S, Heist 
RS, Temel J, Christensen JG, Wain JC, Lynch TJ, Vernovsky K, Mark EJ, 
Lanuti M, Iafrate AJ, Mino-Kenudson M, Engelman JA. Genotypic and 
histological evolution of lung cancers acquiring resistance to EGFR 
inhibitors. 2011;3(75):75ra26. 
58. Kalluri R, Neilson EG. Epithelial-mesenchymal transition and its implications 
for fibrosis. 2003;112(12):1776-84. 
59. Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. 
2009;119(6):1420-8. 
60. Medici D, Hay ED, Olsen BR. Snail and Slug promote epithelial-
mesenchymal transition through beta-catenin-T-cell factor-4-dependent 
expression of transforming growth factor-beta3. 2008;19(11):4875-87. 
61. Palena C, Fernando RI, Litzinger MT, Hamilton DH, Huang B, Schlom J. 
Strategies to target molecules that control the acquisition of a 
mesenchymal-like phenotype by carcinoma cells. 2011;236(5):537-45. 
71 
 
 
 
62. Edme N, Downward J, Thiery JP, Boyer B. Ras induces NBT-II epithelial cell 
scattering through the coordinate activities of Rac and MAPK pathways. 
2002;115(Pt 12):2591-601. 
63. Jenndahl LE, Isakson P, Baeckstrom D. c-erbB2-induced epithelial-
mesenchymal transition in mammary epithelial cells is suppressed by cell-
cell contact and initiated prior to E-cadherin downregulation. 
2005;27(2):439-48. 
64. Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial-mesenchymal 
transitions in development and disease. 2009;139(5):871-90. 
65. Dasari V, Gallup M, Lemjabbar H, Maltseva I, McNamara N. Epithelial-
mesenchymal transition in lung cancer: is tobacco the "smoking gun"? 
2006;35(1):3-9. 
66. Thiery JP, Sleeman JP. Complex networks orchestrate epithelial-
mesenchymal transitions. 2006;7(2):131-42. 
67. Lopez-Novoa JM, Nieto MA. Inflammation and EMT: an alliance towards 
organ fibrosis and cancer progression. 2009;1(6-7):303-14. 
68. Hugo H, Ackland ML, Blick T, Lawrence MG, Clements JA, Williams ED, 
Thompson EW. Epithelial--mesenchymal and mesenchymal--epithelial 
transitions in carcinoma progression. 2007;213(2):374-83. 
69. Lee TK, Poon RT, Yuen AP, Ling MT, Kwok WK, Wang XH, Wong YC, Guan 
XY, Man K, Chau KL, Fan ST. Twist overexpression correlates with 
hepatocellular carcinoma metastasis through induction of epithelial-
mesenchymal transition. 2006;12(18):5369-76. 
70. Lecharpentier A, Vielh P, Perez-Moreno P, Planchard D, Soria JC, Farace F. 
Detection of circulating tumour cells with a hybrid (epithelial/mesenchymal) 
phenotype in patients with metastatic non-small cell lung cancer. 
2011;105(9):1338-41. 
71. Suda K, Tomizawa K, Fujii M, Murakami H, Osada H, Maehara Y, Yatabe Y, 
Sekido Y, Mitsudomi T. Epithelial to mesenchymal transition in an epidermal 
growth factor receptor-mutant lung cancer cell line with acquired resistance 
to erlotinib. 2011;6(7):1152-61. 
72 
 
 
 
72. Savagner P. Leaving the neighborhood: molecular mechanisms involved 
during epithelial-mesenchymal transition. 2001;23(10):912-23. 
73. Singh A, Settleman J. EMT, cancer stem cells and drug resistance: an 
emerging axis of evil in the war on cancer. 2010;29(34):4741-51. 
74. Wang Z, Li Y, Kong D, Banerjee S, Ahmad A, Azmi AS, Ali S, Abbruzzese JL, 
Gallick GE, Sarkar FH. Acquisition of epithelial-mesenchymal transition 
phenotype of gemcitabine-resistant pancreatic cancer cells is linked with 
activation of the notch signaling pathway. 2009;69(6):2400-7. 
75. Thomson S, Buck E, Petti F, Griffin G, Brown E, Ramnarine N, Iwata KK, 
Gibson N, Haley JD. Epithelial to mesenchymal transition is a determinant 
of sensitivity of non-small-cell lung carcinoma cell lines and xenografts to 
epidermal growth factor receptor inhibition. 2005;65(20):9455-62. 
76. Frederick BA, Helfrich BA, Coldren CD, Zheng D, Chan D, Bunn PA,Jr, 
Raben D. Epithelial to mesenchymal transition predicts gefitinib resistance 
in cell lines of head and neck squamous cell carcinoma and non-small cell 
lung carcinoma. 2007;6(6):1683-91. 
77. Witta SE, Gemmill RM, Hirsch FR, Coldren CD, Hedman K, Ravdel L, 
Helfrich B, Dziadziuszko R, Chan DC, Sugita M, Chan Z, Baron A, Franklin 
W, Drabkin HA, Girard L, Gazdar AF, Minna JD, Bunn PA,Jr. Restoring E-
cadherin expression increases sensitivity to epidermal growth factor 
receptor inhibitors in lung cancer cell lines. 2006;66(2):944-50. 
78. Zhang Z, Lee JC, Lin L, Olivas V, Au V, LaFramboise T, Abdel-Rahman M, 
Wang X, Levine AD, Rho JK, Choi YJ, Choi CM, Kim SW, Jang SJ, Park 
YS, Kim WS, Lee DH, Lee JS, Miller VA, Arcila M, Ladanyi M, Moonsamy 
P, Sawyers C, Boggon TJ, Ma PC, Costa C, Taron M, Rosell R, Halmos B, 
Bivona TG. Activation of the AXL kinase causes resistance to EGFR-
targeted therapy in lung cancer. 2012;44(8):852-60. 
79. Byers LA, Diao L, Wang J, Saintigny P, Girard L, Peyton M, Shen L, Fan Y, 
Giri U, Tumula PK, Nilsson MB, Gudikote J, Tran H, Cardnell RJ, Bearss 
DJ, Warner SL, Foulks JM, Kanner SB, Gandhi V, Krett N, Rosen ST, Kim 
ES, Herbst RS, Blumenschein GR, Lee JJ, Lippman SM, Ang KK, Mills GB, 
Hong WK, Weinstein JN, Wistuba II, Coombes KR, Minna JD, Heymach JV. 
An epithelial-mesenchymal transition gene signature predicts resistance to 
EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for 
overcoming EGFR inhibitor resistance. 2013;19(1):279-90. 
73 
 
 
 
80. Postel-Vinay S, Ashworth A. AXL and acquired resistance to EGFR inhibitors. 
2012;44(8):835-6. 
81. Semb H, Christofori G. The tumor-suppressor function of E-cadherin. 
1998;63(6):1588-93. 
82. de Herreros AG, Peiro S, Nassour M, Savagner P. Snail family regulation and 
epithelial mesenchymal transitions in breast cancer progression. 
2010;15(2):135-47. 
83. Darnell JE,Jr. Transcription factors as targets for cancer therapy. 
2002;2(10):740-9. 
84. Kurrey NK, Jalgaonkar SP, Joglekar AV, Ghanate AD, Chaskar PD, 
Doiphode RY, Bapat SA. Snail and slug mediate radioresistance and 
chemoresistance by antagonizing p53-mediated apoptosis and acquiring a 
stem-like phenotype in ovarian cancer cells. 2009;27(9):2059-68. 
85. Bhat-Nakshatri P, Appaiah H, Ballas C, Pick-Franke P, Goulet R,Jr, Badve S, 
Srour EF, Nakshatri H. SLUG/SNAI2 and tumor necrosis factor generate 
breast cells with CD44+/CD24- phenotype. 2010;10:411,2407-10-411. 
86. Zhang YE. Non-Smad pathways in TGF-beta signaling. 2009;19(1):128-39. 
87. Yang J, Weinberg RA. Epithelial-mesenchymal transition: at the crossroads 
of development and tumor metastasis. 2008;14(6):818-29. 
88. Shih JY, Yang PC. The EMT regulator slug and lung carcinogenesis. 
2011;32(9):1299-304. 
89. Peinado H, Quintanilla M, Cano A. Transforming growth factor beta-1 induces 
snail transcription factor in epithelial cell lines: mechanisms for epithelial 
mesenchymal transitions. 2003;278(23):21113-23. 
90. De Craene B, van Roy F, Berx G. Unraveling signalling cascades for the 
Snail family of transcription factors. 2005;17(5):535-47. 
91. Cano A, Perez-Moreno MA, Rodrigo I, Locascio A, Blanco MJ, del Barrio MG, 
Portillo F, Nieto MA. The transcription factor snail controls epithelial-
mesenchymal transitions by repressing E-cadherin expression. 
2000;2(2):76-83. 
74 
 
 
 
92. Chang TH, Tsai MF, Su KY, Wu SG, Huang CP, Yu SL, Yu YL, Lan CC, 
Yang CH, Lin SB, Wu CP, Shih JY, Yang PC. Slug confers resistance to the 
epidermal growth factor receptor tyrosine kinase inhibitor. 
2011;183(8):1071-9. 
93. Haslehurst AM, Koti M, Dharsee M, Nuin P, Evans K, Geraci J, Childs T, 
Chen J, Li J, Weberpals J, Davey S, Squire J, Park PC, Feilotter H. EMT 
transcription factors snail and slug directly contribute to cisplatin resistance 
in ovarian cancer. 2012;12:91,2407-12-91. 
94. Kim JJ, Yin B, Christudass CS, Terada N, Rajagopalan K, Fabry B, Lee DY, 
Shiraishi T, Getzenberg RH, Veltri RW, An SS, Mooney SM. Acquisition of 
paclitaxel resistance is associated with a more aggressive and invasive 
phenotype in prostate cancer. 2013;114(6):1286-93. 
95. Barr S, Thomson S, Buck E, Russo S, Petti F, Sujka-Kwok I, Eyzaguirre A, 
Rosenfeld-Franklin M, Gibson NW, Miglarese M, Epstein D, Iwata KK, 
Haley JD. Bypassing cellular EGF receptor dependence through epithelial-
to-mesenchymal-like transitions. 2008;25(6):685-93. 
96. Thomson S, Petti F, Sujka-Kwok I, Epstein D, Haley JD. Kinase switching in 
mesenchymal-like non-small cell lung cancer lines contributes to EGFR 
inhibitor resistance through pathway redundancy. 2008;25(8):843-54. 
97. Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, 
Lindeman N, Gale CM, Zhao X, Christensen J, Kosaka T, Holmes AJ, 
Rogers AM, Cappuzzo F, Mok T, Lee C, Johnson BE, Cantley LC, Janne 
PA. MET amplification leads to gefitinib resistance in lung cancer by 
activating ERBB3 signaling. 2007;316(5827):1039-43. 
98. Arteaga CL. HER3 and mutant EGFR meet MET. 2007;13(6):675-7. 
99. Lin L, Bivona TG. Mechanisms of Resistance to Epidermal Growth Factor 
Receptor Inhibitors and Novel Therapeutic Strategies to Overcome 
Resistance in NSCLC Patients. 2012;2012:817297. 
100. Peled N, Wynes MW, Ikeda N, Ohira T, Yoshida K, Qian J, Ilouze M, 
Brenner R, Kato Y, Mascaux C, Hirsch FR. Insulin-like growth factor-1 
receptor (IGF-1R) as a biomarker for resistance to the tyrosine kinase 
inhibitor gefitinib in non-small cell lung cancer. 2013;36(4):277-88. 
75 
 
 
 
101. Lee HY, Srinivas H, Xia D, Lu Y, Superty R, LaPushin R, Gomez-Manzano 
C, Gal AM, Walsh GL, Force T, Ueki K, Mills GB, Kurie JM. Evidence that 
phosphatidylinositol 3-kinase- and mitogen-activated protein kinase kinase-
4/c-Jun NH2-terminal kinase-dependent Pathways cooperate to maintain 
lung cancer cell survival. 2003;278(26):23630-8. 
102. Buchsbaum DJ, Bonner JA, Grizzle WE, Stackhouse MA, Carpenter M, 
Hicklin DJ, Bohlen P, Raisch KP. Treatment of pancreatic cancer xenografts 
with Erbitux (IMC-C225) anti-EGFR antibody, gemcitabine, and radiation. 
2002;54(4):1180-93. 
103. Perez R, Crombet T, de Leon J, Moreno E. A view on EGFR-targeted 
therapies from the oncogene-addiction perspective. 2013;4:53. 
104. Fan F, Samuel S, Evans KW, Lu J, Xia L, Zhou Y, Sceusi E, Tozzi F, Ye 
XC, Mani SA, Ellis LM. Overexpression of snail induces epithelial-
mesenchymal transition and a cancer stem cell-like phenotype in human 
colorectal cancer cells. 2012;1(1):5-16. 
105. Peinado H, Olmeda D, Cano A. Snail, Zeb and bHLH factors in tumour 
progression: an alliance against the epithelial phenotype? 2007;7(6):415-
28. 
106. Lim S, Becker A, Zimmer A, Lu J, Buettner R, Kirfel J. SNAI1-mediated 
epithelial-mesenchymal transition confers chemoresistance and cellular 
plasticity by regulating genes involved in cell death and stem cell 
maintenance. 2013;8(6):e66558. 
107. Hoshino H, Miyoshi N, Nagai K, Tomimaru Y, Nagano H, Sekimoto M, Doki 
Y, Mori M, Ishii H. Epithelial-mesenchymal transition with expression of 
SNAI1-induced chemoresistance in colorectal cancer. 2009;390(3):1061-5. 
108. Cho HJ, Baek KE, Saika S, Jeong MJ, Yoo J. Snail is required for 
transforming growth factor-beta-induced epithelial-mesenchymal transition 
by activating PI3 kinase/Akt signal pathway. 2007;353(2):337-43. 
109. Zhang K, Jiao X, Liu X, Zhang B, Wang J, Wang Q, Tao Y, Zhang D. 
Knockdown of snail sensitizes pancreatic cancer cells to chemotherapeutic 
agents and irradiation. 2010;11(12):4891-2. 
76 
 
 
 
110. Azmi AS, Mohammad RM, Sarkar FH. SNAIL inhibitor GN-25 induces MET 
through Global Reprograming of EMT Network Genes: a Systems and 
Network Analysis. July 1, 2012;72(13). 
111. Harney AS, Meade TJ, LaBonne C. Targeted inactivation of Snail family 
EMT regulatory factors by a Co(III)-Ebox conjugate. 2012;7(2):e32318. 
112. Sun M, Guo X, Qian X, Wang H, Yang C, Brinkman KL, Serrano-Gonzalez 
M, Jope RS, Zhou B, Engler DA, Zhan M, Wong ST, Fu L, Xu B. Activation 
of the ATM-Snail pathway promotes breast cancer metastasis. 
2012;4(5):304-15. 
 
 
 
 
 
77 
 
VITA 
 Rutu Gandhi was born in Mumbai, India on March 24, 1989 to Rupa and 
Shailesh Gandhi. She received Bachelor of Pharmaceutical Sciences degree from 
Gujarat University (Ahmedabad, India) in May 2011.  
 While studying pharmaceutical science, Rutu got interested in studying 
cancer therapeutics and decided to move to United States to explore the field of 
cancer drug research. In August of 2011, Rutu joined the department of Molecular 
Pharmacology & Experimental Therapeutics at Loyola University Medical Center 
(Maywood, IL). Shortly thereafter, she joined the laboratory of Dr. Takeshi 
Shimamura where she studied epithelial to mesenchymal transition as a mechanism 
of resistance to epidermal growth factor receptor tyrosine kinase inhibitors in EGFR 
mutant non-small cell lung cancer.  
 After finishing her M.S., Rutu plans to work as a researcher in 
pharmaceutical industry to continue her pursuit of exploring the field of cancer 
drug research. 
